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ABSTRACT 
Danielle M. Backes: Natural history of human papillomavirus infection among young 
men from Kisumu, Kenya 
(Under the direction of Jennifer S. Smith, PhD, MPH) 
 
Human papillomavirus (HPV) infection is necessary for the development of 
invasive cervical cancer among women and is a risk factor of other anogenital 
cancers among women and men. Among men, data on the natural history of HPV 
infection and on risk factors of HPV-associated penile lesions are limited.  
An HPV-ancillary study, nested within a randomized controlled trial (RCT) of 
male circumcision, was conducted in Kisumu, Kenya from 2002-2007. All 
participants were human immunodeficiency virus seronegative, uncircumcised and 
aged 17-24 years at baseline. Penile exfoliated cell specimens were collected at 
baseline, 12 and 24-month visits from the glans/coronal sulcus and shaft of 
participating men and tested using GP5+/6+ polymerase chain reaction. An 
additional visual inspection exam with acetic acid was conducted at the 24-month 
visit to determine the presence of colposcopy-detected penile lesions. 
For incidence and persistence analyses, 949 participants enrolled in the 
control arm of the main RCT were included. Median follow-up time was 24.2 months 
(range 11.6-30.4). The incidence of any HPV infection was 24.3/1,000 person-
months. A total of 18.3% (95% confidence interval [CI]: 15.0-22.3) of incident HPV 
infections in the glans persisted from the 12 to 24-month visits and 13.5% (95% CI: 
11.1-16.3) of prevalent HPV infections in the glans persisted from baseline until at 
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least the 12-month visit. HPV clearance was similar for high-risk versus low-risk 
infections and by age group. 
Of 267 men participating in visual inspection exams from both arms of the 
RCT, 143 were circumcised and 124 uncircumcised. Circumcised men had a lower 
prevalence of flat penile lesions (0.7%) versus uncircumcised men (26.0%); age-
adjusted odds ratio (OR)=0.02; 95% CI: 0.003-0.1. Men with flat lesions had 
increased odds of HPV DNA positivity and high HPV16/18/31 viral load compared to 
men without flat lesions.  
The natural history of HPV infection among men may be different than that 
previously described for women, with a relatively high incidence of penile HPV 
infection found among men. Differences in patterns of high and low-risk HPV 
clearance between men and women may also exist. This study suggests male 
circumcision reduces the prevalence of HPV-associated flat penile lesions and may 
reduce HPV transmission between sexual partners. 
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CHAPTER 1. 
STATEMENT OF SPECIFIC AIMS 
 
Human papillomavirus (HPV) infection is a widespread sexually transmitted 
infection (STI) and the main etiologic cause of invasive cervical cancer (ICC) among 
women (1). HPV infection is also considered an important risk factor in non-cervical 
cancers including anal and penile cancers in men (2-4). While numerous studies 
have investigated HPV infection among women, data on the natural history of HPV 
infection are limited in men, especially from less developed regions including Africa 
(5). Data are also needed on risk factors of HPV-associated penile lesions. 
An HPV-ancillary study was nested within a randomized controlled trial (RCT) 
that began in Kisumu, Kenya in February 2002 with the primary aim of determining 
the effect of male circumcision on human immunodeficiency virus (HIV) incidence 
(6). All men participating in the main RCT were invited to participate in the HPV 
study, which involved testing penile exfoliated cell specimens collected from two 
anatomical sites (the glans/coronal sulcus and shaft) from men at the baseline, 12 
and 24-month visits. A sensitive GP5+/6+ polymerase chain reaction (PCR) assay 
was used to detect a wide range of individual HPV types. An incident or acquired 
infection was defined as the detection of an HPV type at the 12 or 24-month follow-
up visits not detected at baseline. Persistence of incident HPV infection (i.e. incident 
persistence) was defined as repeat positivity for a type-specific HPV infection at the 
12 and 24-month follow-up visits that was not detected at baseline. Persistence of a 
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prevalent HPV infection (i.e. prevalent persistence) was defined as repeat positivity 
at two or more consecutive visits for a type-specific HPV infection detected at 
baseline. An additional clinical examination (a visual inspection of the penis with 3% 
acetic acid [VIA] and aided magnification), was conducted at the 24-month visit to 
determine the presence of colposcopy-detected penile lesions (flat lesions, 
condyloma acuminata, papular lesions, and pearly penile papules) among 267 
consenting participants. 
 
With the data collected from this study, the following research aims were addressed: 
 
Specific Aim 1: To investigate the natural history of HPV infection (incidence, 
incident persistence, prevalent persistence/clearance) in a cohort of 
uncircumcised Kenyan men aged 17-24.   
Hypothesis: The 24-month incidence rate (IR) for the first overall HPV type 
detected will be within the range of 18-35/1,000 person-months. The overall type-
specific persistence over 12 months of both incident and prevalent HPV infections 
will range between 20-40%.  
Rationale: Few studies have been published on the incidence and 
persistence of HPV infections among men. These data are important given that men 
are an important factor for increased risk of HPV infection and ICC in their female 
sexual partners (7), and since HPV infection is associated with penile and anal 
cancers among men (2;3). Data on the natural history of HPV infection among men 
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are especially needed from less developed regions, including sub-Saharan Africa 
where the burden of ICC is among the highest worldwide (8;9).   
 
Specific Aim 2: To determine the association between penile lesions and HPV 
DNA positivity, HPV viral load and socio-demographic risk factors of 
ascertained HPV-associated penile lesions. 
Hypothesis: Lack of circumcision, higher HPV viral load, lack of condom use 
and a higher number of sexual partners are risk factors of HPV-associated penile 
lesions among Kenyan men. 
Rationale: Interventions that reduce HPV-associated penile lesions could be 
important to both men and women, since HPV-associated penile lesions in men may 
increase the risk of HPV transmission to their sexual partners (10). Risk factor data 
on HPV-associated penile lesions are needed, especially from less-developed 
regions with a high burden of HPV-associated cancers. To my knowledge this is the 
first study to investigate whether circumcision reduces the prevalence of flat penile 
lesions and the first to assess multiple risk factors of HPV-associated penile lesions 
among men from sub-Saharan Africa.  
 
 
 
 
 
 
CHAPTER 2. 
BACKGROUND AND SIGNIFICANCE 
 
HPV and Anogenital Cancers 
Cervical cancer is the second most common cancer among women worldwide 
with an estimated incidence of 493,000 new cases each year and the leading cause 
of cancer related deaths among women in less-developed countries (8;9). The 
burden of ICC is particularly high in Eastern Africa, which has the highest annual, 
age-standardized IR of ICC worldwide (42.7/100,000 women/year) (8;9).  
It is now well established that genital HPV infection, a common STI, is a 
necessary cause for the development of ICC as HPV infection has been identified in 
almost all biopsy specimens of ICC using sensitive PCR assays (11). Approximately 
40 different types of HPV have been associated with anogenital infection, of which 
13-15 are classified as oncogenic (i.e. high-risk) types due to their association with 
ICC (e.g. HPV16 and 18) (12;13). HPV16 and 18 have been found in approximately 
60-70% of cervical cancers worldwide and therefore, appear to be the predominant 
oncogenic types (12). Other HPV types (e.g. HPV6 and 11) are considered non-
oncogenic (i.e. low-risk) since they are rarely found in invasive cervical disease 
(12;14). The prevalence of HPV infection in Kenya has been reported between 17-
43% among women 19-55 years of age attending family planning clinics in Nairobi 
(15;16) and 51%-58% among men aged 17-63 in Kisumu (17;18). 
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HPV infection is also associated with other female anogenital cancers as HPV 
DNA has been detected in approximately 40%, 66% and 87% of invasive vulvar, 
vaginal and anal cancers in women, respectively (3;19). HPV also appears to play a 
role in both anal and penile cancers in men. HPV DNA has been detected in 
approximately half (48%) of penile cancers and 77% of anal cancers among men 
worldwide (2;3). 
 
The Male Role in the Etiology of Cervical Cancer and in HPV Transmission  
Men were considered to have an important role in the etiology of cervical 
cancer even before HPV infection was identified as its central cause (20).  As early 
as 1976, an increased risk of cervical cancer was found among wives of men who 
were previously married to women with cervical cancer (21). Numerous studies have 
also shown that a woman’s risk of cervical cancer increased with her husband’s 
reported number of lifetime sex partners (22;23) and if he had premarital or 
extramarital sexual relationships (24). Further, a husband’s sexual history was found 
to be a risk factor of his wife’s cervical disease even after adjusting for both her 
reported number of sex partners and age at first intercourse (25). 
Studies investigating HPV prevalence in men among heterosexual couples 
further supported the importance of the men in the etiology of cervical cancer and 
their potential to transmit HPV infection to their female partners. Numerous studies 
have reported a higher prevalence of HPV among husbands of women with cervical 
cancer compared to those of women without cervical cancer or cervical 
intraepithelial neoplasia (CIN) (26-28). A wide range of HPV type concordance 
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among HPV-positive couples have been reported in the literature ranging from 
22.7% to 100% (10). HPV type concordance was higher than expected by chance in 
a study of 50 couples attending an STI clinic (29) and in a study of 238 heterosexual 
couples where the female partner had CIN (30), providing indirect evidence of HPV 
transmission among sexual partners. Higher HPV viral loads have also been found 
among HPV concordant men compared to those that were not HPV concordant with 
their female partners (30).  
 
Ascertainment of Penile HPV DNA 
While many studies have been conducted to characterize HPV infection 
among women, data on HPV infection in men are more limited. Initial studies of HPV 
infection in men used aceto-white penile lesions detected by visual inspection as a 
diagnostic marker for HPV infection (4). However, because of the poor specificity of 
peniscopy for HPV detection, exfoliated cells or biopsy specimens and molecular 
techniques such as PCR are strongly recommended in order to accurately assess 
HPV infection in men (4).   
In a systematic review, Dunne et al (5) summarized studies of HPV 
prevalence in men that used sensitive PCR or hybrid capture assays and were 
published between 1990-2006. There was a wide range of reported estimates for 
HPV prevalence among study populations ranging from 1.3% among university 
students in Japan (31) to 72.9% among male partners of women with CIN in the 
Netherlands (30). While some of the differences in prevalence estimates can likely 
be attributed to differences in study populations, it has also been suggested that a 
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large part of the variability in HPV prevalence estimates is due to incomplete 
specimen sampling (32).  
In a study that included a wide range of anatomical sites for specimen 
sampling (penile shaft/prepuce, glans/coronal sulcus, scrotum, perianal, anal canal, 
urethra and semen), HPV prevalence was highest in the penile shaft and 
glans/coronal sulcus (49.9% and 35.8%, respectively) (32). The authors 
recommended that the shaft and glans/coronal sulcus should be the minimum sites 
sampled when estimating HPV prevalence in men. Sampling from the scrotum, 
perianal or anal canal was also suggested for optimal penile HPV detection.  A small 
decrease in HPV positivity was found by excluding the scrotal, perianal and anal 
canal samples (2.1%, 2.6% and 3.2%, respectively). There was no decrease in HPV 
positivity by excluding urethra and semen samples over that found when sampling 
all other sites. 
In another study that evaluated genital sites for HPV DNA detection in men 
(33), the following sites were recommended for HPV sampling: penile shaft, glans, 
coronal sulcus, scrotum and urine. Sampling from the scrotum and urine however, 
did not increase sensitivity for uncircumcised men. Among circumcised men, a small 
percentage of men had HPV DNA detected in the scrotal or urine sample (2.6% at 
each site) but not at the shaft or glans. Semen sampling did not increase the 
sensitivity of sampling for HPV DNA.  
Other studies are consistent with the findings that a sample from the urethra 
does not substantially increase the sensitivity of HPV DNA detection (34;35). 
Urethral sampling is often painful and could likely decrease participation, especially 
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in follow-up studies. Thus, it has been suggested that urethral sampling is not 
necessary for inclusion in large studies of HPV detection in men (35).   
 
Natural History of HPV Infection in Men 
Seven longitudinal studies (N>20) have been conducted to assess the natural 
history of HPV infection in men (36-42) and two reports from a RCT of HPV and 
male circumcision conducted in Rakai, Uganda provide HPV natural history data for 
men participating in the control arm of the trial (43;44) (Table 2.1). The IR of HPV 
infections for the first overall type detected has been found to range from 17.9/1,000 
person-months among military men from Mexico (37) to 34.9/1,000 person-months 
among male university students in the United States (39). Type-specific persistence 
of HPV infection over one year has been found to range between 25-30% among 
HPV-positive men (36;37). Two previous studies reported a median time to HPV 
clearance ranging from 3.6-5.9 months (36;42), while one previous study reported a 
clearance rate of 19.1/1,000 person-months (43). 
The same IR of 29.4/1,000 person-months for HPV infection was reported for 
290 men from Tucson, Arizona (36) and among 331 women from the same city 
using a similar study design and method of HPV detection (45).  While the 12-month 
cumulative incidence for acquiring high and low-risk HPV infections were similar 
among men (0.19 and 0.16, respectively), women were more likely to acquire a high-
risk than low-risk infection (0.32 vs. 0.18, respectively). A comparable median time 
to clearance among men for high and low-risk HPV types was observed (5.8 and 6.0 
months, respectively) in comparison with a higher median time to clearance for high-
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risk types (9.8 months) compared to low-risk types (4.3 months) among women. In 
contrast, Lajous et al (37) and Kjaer et al (38) found a higher risk of persistence for 
high versus low-risk HPV types among men, which is consistent with natural history 
studies among women (46-48).  
Partridge et al reported a 24-month cumulative incidence of 62.4% (95% 
confidence interval [CI]: 52.6-72.2) among a cohort of 240 male university students 
(39). This estimate was higher than the corresponding 24-month cumulative 
incidence found among a cohort of 553 women at the same university (38.8% [95% 
CI: 33.3-45.0]) (49). The 12-month cumulative incidence among men in this study 
(35%) (39) was slightly higher than that reported by Giuliano et al (35%) (36). 
Four previous studies have investigated multiple risk factors of HPV incidence 
or persistence in men (37-39;50). Risk factors of incident HPV infection include past 
smoking (39), recent and lifetime number of sex partners (38;39;50), high socio-
economic status (37), anal intercourse with men (37), and condom use (38). Risk 
factors associated with persistent HPV infection were lack of male circumcision 
(37;50) and multiple HPV types detected at baseline (37;38). 
Additionally, three recent studies investigated the effect of male circumcision 
on the incidence and clearance of HPV infection (42-44). In a RCT of HPV and male 
circumcision conducted in Rakai, Uganda, circumcision increased the acquisition 
rate and decreased the clearance rate of HPV infection among men who were HIV-
negative at enrolment (43), although no difference in HPV acquisition or clearance 
was found by circumcision status among men HIV-positive at enrolment (44). 
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Hernandez et al (42) also found reduced clearance of HPV infection among 
uncircumcised men compared to circumcised men in an observational study.   
 
Penile Lesions 
Definitions of penile lesions 
Flat penile lesions are defined as flat or slightly elevated, well demarcated, 
aceto-white lesions and are considered a manifestation of productive high-risk HPV 
infection in men (Table 2.2) (10;51). These lesions are often referred to as 
subclinical lesions since they are only visible after aceto-white staining. The 
application of acetic acid can be use to distinguish flat lesions from other conditions 
that are visible and often white in color without the use of acetic acid, such as 
psoriasis or yeast infections (10). Condyloma acuminata, commonly known as 
genital warts, are elevated lesions with an irregular surface, visible without acetic 
acid application and associated with low-risk HPV infection (4;51). Papular lesions 
are small elevated papules with a smooth surface usually located near the frenulum, 
while pearly penile papules are small exophytic lesions located around the corona of 
the glans penis (51;52). Papular lesions and pearly penile papules are visible without 
application of 3% acetic acid and have not been previously associated with HPV 
infection (Table 2.2).   
 
Prevalence of penile lesions 
Penile lesions are frequently seen in male sex partners of women with CIN 
(51;53-55) and a higher prevalence of aceto-white lesions has been found among 
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male partners of women with CIN compared to women without cervical disease 
(53;54;56). The prevalence of flat lesions and condyloma acuminata among male 
partners of women with CIN has been found to range between 29-60% and 5-24%, 
respectively (10). Among male partners of women without known HPV infection, the 
prevalence of penile lesions was lower, ranging between 4-36% for flat lesions and 
0-6% for condyloma (10). Flat lesions have also been found to be larger in size 
among male partners of women with CIN compared to a hospital population with no 
known STIs (56). 
 
HPV and penile lesions 
In a study of 175 male sex partners of women with CIN, HPV prevalence was 
higher in penile exfoliated cells among men with penile lesions (flat, papular, or 
condyloma acuminata) compared to those without lesions (67 vs. 37%, respectively) 
(51). HPV infection was associated with flat lesions as HPV DNA was detected in 41 
(72%) of 57 flat lesions compared with 16 (25%) flat lesions that were negative for 
HPV DNA. Of the HPV-positive flat lesions, the majority (93%) contained high-risk 
HPV DNA. Higher HPV viral loads were also associated with the presence of flat 
lesions (56). Thus, male sex partners may be a ‘reservoir’ for high-risk HPV infection 
and flat penile lesions are likely an important factor in the spread of HPV infection 
between couples (10).  
Further, condom use was associated with the median time to regression of 
penile lesions (hazard ratio=2.1, 95% CI: 1.2-3.7 for condom use vs. non-use), 
especially among HPV concordant couples (hazard ratio=2.63, 95% CI: 1.07-6.48) 
12 
(57;58). Condom use, therefore, may prevent the spread of HPV between partners, 
and re-infection with the same HPV type may increase the risk of penile lesion 
development (10).  
More than 90% of genital warts are associated with low-risk HPV types 6 and 
11 while high-risk HPV types are rarely detected (4). This is consistent with three 
studies of penile lesions which reported an HPV6 or 11 prevalence of between 80-
100% among HPV-positive genital warts (53;59;60). HPV infection does not appear 
to be associated with papular lesions as HPV was detected in 5 (62%) of the 8 
ascertained papular lesions in a study of 175 men (51). These results are consistent 
with an earlier study of 270 men which did not find an association between HPV 
DNA and papular lesions (59), although the number of ascertained papular lesions in 
both studies was small. Pearly penile papules are also not considered to be related 
to HPV infection based on a study of 226 male partners of women with CIN where 
the prevalence of pearly penile papules was not associated with HPV positivity (52). 
These results were consistent with a previous study that failed to detect HPV DNA in 
any of the 13 biopsy specimens of pearly penile papules tested by PCR (61). 
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Table 2.1 Characteristics and findings of natural history studies of human papillomavirus (HPV) in men.  
Reference 
Study 
location 
Study 
population 
Study 
size 
PCR 
primer Sites sampled 
 Median 
follow-up, 
months 
(range) 
HPV 
type 
Incident 
HPV %* 
Cumulative 
Incidence 
Incidence 
rate/ 1000 
person-
months 
 Persistent 
HPV %
†
 
Median 
time to 
clearance 
(months) 
Low-risk populations                       
Hernandez 
2010 (42) HI, US 
University 
population 357 
PGMY09
/11 
glans, coronal 
sulcus, shaft, 
scrotum  
14.2 (1.2-
41.5) Any NS NS NS NS 3.6-3.9 
             
Gray 2010 
(43) Uganda 
Control arm 
RCT 
participants 399 
MY09/11
+HMB01 
Glans, coronal 
sulcus 24 (NS) HR NS NS 24.5 NS 19.1
‡
 
       16 NS NS 4.0 NS 20.1
‡
 
             
Giuliano 
2008 (36) AZ, US 
AZ 
residents 290 MY09/11 
glans, coronal 
sulcus, shaft, 
scrotum 
15.5 (3.7-
24.7) Any 32.5 29.2 (12 m) 29.4 25.5 (12m) 5.9 
       HR 18.2 19 15.5 19.0 5.8 
       LR 18.1 16 15.4 29.3 6.0 
       16 6.0  4.8   
             
Partridge 
2007 (39) WA, US 
University 
students 240 
MY09/11 
+HMB01 
glans, shaft, 
scrotum 12.9 (NS) Any 41.4 62.4 (24 m) 34.9 49.2 NS 
       HR 30.7 47.9 24.7 NS NS 
       LR 28.1 46.6 22.8 NS NS 
       16 13.2 19.5 10.0 NS NS 
             
Lajous 2005 
(37) Mexico Military men 336 
BGH 20, 
BPCO4 
coronal sulcus, 
shaft, scrotum, 
urethral 
meatus, urethra 12 (NS) Any 21.4 NS 17.9 29.4 NS 
       HR 14.3 NS 11.9 31.0 NS 
       LR 12.7 NS 10.6 23.1 NS 
       16 2.8 NS 2.3 31.3 NS 
             
Kjaer 2005 
(38) Denmark 
Male 
conscripts 250 Gp5+6+ 
glans, coronal 
sulcus 
6.6 (mean) 
(5.4-7.8) Any 13.8 NS NS 57.5 NS 
       
non-16 
HR NS NS NS 56 NS 
       LR NS NS NS 35 NS 
       16 2.6 NS NS 63 NS 
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Table 2.1 continued            
 
 
Reference 
Study 
location 
Study 
population 
Study 
size 
PCR 
primer Sites sampled 
 Median 
follow-up, 
months 
(range) 
HPV 
type 
Incidence 
%* 
Cumulative 
Incidence 
Incidence 
rate/ 1000 
person-
months 
 
Persistent
%
†
 
Median 
time to 
clearance 
(months) 
Low-risk populations continued           
de Sanjose 
2003 (62) 
Spain, 
Columbia 
Husbands 
of study 
participants 14 
PMY 
09/11 
PCR L1 urethra 
108 (84-
132) Any NS NS NS 14.3 NS 
            
High-risk populations            
Serwadda 
2010 (44) Uganda 
HIV+ 
control arm 
RCT 
participants 107 
MY09/11
+HMB01 
Glans, coronal 
sulcus NS Any 57.0 NS NS 29.0 NS 
       16 14.9 NS NS 36.8 NS 
             
Wikstrom 
2000 (40) Sweden 
STD clinic 
attendees 88 GP5+6+ 
glans, coronal 
sulcus 
3.5 (0.5-
16) Any 22.4 NS NS 50 NS 
             
Van 
Doornum 
1994 (41) 
the 
Netherlands 
STD clinic 
attendees 48 TS 
coronal sulcus, 
urethra, anus, 
rectum 16.4 (NS) Any 42.4 NS 42** 20
††
 NS 
NS: not specified; RCT: randomized controlled trial; HR: high-risk; LR: low-risk; HIV: human immunodeficiency virus; STD: sexually transmitted disease; TS: type-specific 
* Percentage of men who were HPV negative (for specified HPV type) at baseline 
† 
Percentage of HPV-positive (for specified HPV type/group) men at baseline 
‡
 HPV clearance rate per 1,000 person-months 
** Numerator is newly acquired infections ( >1 infection/man is possible) 
††
 Percentage of HPV infections (> 1 infection per man is possible) 
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Table 2.2 Description and characteristics of different types of penile lesions (51;52) 
Type of Lesion Description 
Associated with 
HPV infection? 
Visible without acetic 
acid application? 
 
Flat lesions  
 
 
Flat or slightly elevated, well 
demarcated, aceto-white lesions 
  
 
Yes 
 
No 
Condyloma acuminata  
(i.e. genital warts)  
Elevated lesions with an irregular 
surface  
 
Yes Yes 
Papular Lesions  Small exophytic papules with a 
smooth surface usually located 
near the frenulum  
 
No Yes 
Pearly Penile Papules Small exophytic papules located 
around corona of the glans penis  
 
No Yes 
 
  
 
 
 
 
 
CHAPTER 3. 
METHODS 
 
 
An HPV-ancillary study was nested within a RCT of male circumcision 
conducted in Kisumu, Kenya (6). Men enrolled in the main RCT were invited to 
participate in the nested HPV study which involved testing penile exfoliated cell 
specimens collected at baseline (i.e. randomization visit), and the 12 and 24-month 
follow-up visits for HPV DNA. RCT participants consented to the HPV study by 
checking a box on the main RCT consent form. 
Men from both arms of the main RCT were also invited to participate in a 
visual inspection examination with 3% acetic acid at the 24-month visit in order to 
determine the prevalence of colposcopy-detected penile lesions (e.g. HPV-
associated flat lesions, papular lesions). This was an additional exam added on to 
the main RCT protocol and required a separate informed consent form to be 
administered at the 24-month visit.  
 
RCT of Male Circumcision for HIV Prevention: Bailey et al, 2007 
A RCT with the primary aim of determining the effect of male circumcision on 
HIV incidence was conducted in Kisumu, Kenya beginning in February 2002 (6). The 
eligibility criteria for the main trial are listed in Table 3.1.  
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Recruitment process and screening visit 
 
Study subjects were recruited and enrolled in the study from February 4, 2002 
until September 6, 2005. Subjects were recruited from multiple places including STI 
clinics, workplaces and community organizations. Free transportation was provided 
to the study clinic. Compensation for time and general health care and treatment 
were also provided to all recruited subjects. At the screening visit, the study was 
explained in more detail, HIV testing and counseling was provided, blood 
hemoglobin levels were tested and a brief examination was conducted to assess 
circumcision status. Any subject that was HIV negative and had a blood hemoglobin 
≥90 g/L was invited to enroll in the study and given a consent form to take with them 
and read in detail. 
 
Randomization visit 
During the randomization, or baseline visit, a trained counselor reviewed the 
informed consent with the subject in detail and consenting participants had blood 
drawn, a medical history taken, a medical exam and an interview to obtain socio-
demographic and health information. Urine samples were tested for N. gonorrhea 
and C. trachomatis infections by PCR-based methods (Roche Diagnostics). Sera 
were tested for herpes simplex virus type-2 (HSV-2) antibodies using a type-specific 
enzyme-linked immunosorbent assay (ELISA) (Kalon). Serum specimens were also 
tested for HIV antibody using two rapid tests (Determine, Abbott Diagnostic Division, 
Hoofddorp, the Netherlands; Trinity Biotech, Wicklow, Ireland) and confirmed by 
double ELISA (Adaltis Inc, Montreal, Canada; Trinity Biotech, Wicklow, Ireland) at 
the University of Nairobi.   
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A total of 2,784 participants met the eligibility criteria and were randomly 
assigned by block randomization to the intervention group (i.e. immediate 
circumcision) and were circumcised (n=1391), or to the control group (i.e. delayed 
circumcision; n=1393). Circumcision was performed on the same day or within a few 
days of the baseline visit. Circumcised men were counseled to abstain from sex for 
30 days after surgery due to increased risk of HIV and STIs through their open 
wound. They were also checked for complications at 3 days, 8 days and one month 
after the circumcision procedure. Both circumcised and uncircumcised participants 
were provided with HIV testing and counseling one and three months after 
randomization. 
 
Follow-up visits 
Study participants were followed up at approximately 6, 12, 18 and 24 months 
after randomization. At each follow-up visit, a behavioral risk assessment, HIV 
testing and counseling, STI testing and treatment, and counseling in HIV and STI 
prevention were conducted according to the same protocol used at the baseline visit. 
Men were also allowed to come to the clinic for an unscheduled medical visit at any 
time during follow-up if needed and all men were offered circumcision at the end of 
(24-month) follow-up. 
 
Design of the Nested HPV Study 
Population  
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Men enrolling in the main RCT of HIV and male circumcision (6) constituted 
the source population of the nested HPV study.   
 
There was one additional eligibility criterion for the HPV study: 
• Willing and able to give informed consent for the collection of penile exfoliated cell 
specimens at the baseline, 12 and 24-month visits and for the shipment of these 
specimens to Amsterdam for HPV testing and storage.  
 
There was one additional eligibility criterion for the VIA sub-study: 
•  Willing and able to give informed consent for the VIA examination at the 24-month 
visit. 
 
Collection of penile exfoliated cell specimens 
Penile exfoliated cell specimens were collected by a trained physician or 
clinical officer working as part of the main RCT at the randomization visit prior to 
circumcision (i.e. baseline) and the 12 and 24-month follow-up visits. Specimens 
were collected from two different anatomical sites: i. the penile shaft and external 
foreskin (i.e. shaft specimen) and ii. the glans, coronal sulcus, and the internal tissue 
of the foreskin (i.e. the glans specimen).  
Two sterile 15 ml centrifuge tubes with 2-mL of 0.01 mol/L Tris-HCl 7.4 pH 
buffer were prepared for each patient and labeled with the participant’s ID number, 
the visit number and type of specimen (glans or shaft). A pre-wetted type 3 Dacron 
swab was used to collect exfoliated cells for the shaft specimen and then another 
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separate pre-wetted swab was used to collect exfoliated cells for the glans specimen 
(18).  
For the shaft specimen, exfoliated cells were collected by rubbing the four 
sides of the external shaft tissue from the proximal to distal penile shaft with 
sufficient pressure. The shaft specimen also included a sample from the external 
surface of the foreskin for uncircumcised men.  
For the glans specimen, exfoliated cells were collected by swabbing the tip of 
the urethral opening (completely circling around the urethral orifice 2-3 times). Using 
the same pre-wetted swab, a sample was taken from the glans (by sampling back 
and forth from the top to the bottom in a circular motion) and then from the coronal 
sulcus (by rotating the swab three times around its circumference). For 
uncircumcised men, the prepuce was gently retracted before sampling and a sample 
from the inner foreskin tissue was also included.  
 
Processing of collected specimens 
On the same day as sample collection, each swab was placed in the 
previously labeled centrifuge tubes (a different tube for each specimen), processed 
and centrifuged at high speed for 10 minutes in the clinic laboratory (18). The 
supernatant was discarded using a Pasteur pipette, and the pellet was resuspended 
in the same volume of 0.01mol/L of Tris-HCl buffer and vortexed.  Diluted cell pellets 
were frozen and stored at -75°C. All samples were transported via Fedex in a dry 
shipper (with permission from the Kenyan Ministry of Health) from Kisumu to the 
Department of Pathology at the VU Medical Center in Amsterdam, the Netherlands 
for HPV DNA testing.  
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HPV DNA testing  
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system 
(Hamilton, Germany) according to manufacturers’ instructions. In order to assess the 
quality of the DNA samples, the penile exfoliated cell pellets were evaluated for the 
presence of human DNA by beta-globin specific PCR using BGPCO3 and BGPCO5 
primers (63). An initial 4 minute denaturation step at 94˚C occurred followed by 40 
PCR amplification cycles. Each cycle consisted of a 1 minute denaturation step at 
94˚C, a 2 minute primer annealing step at 58˚C, and a 1.5 minute chain elongation 
step at 72˚C. The last elongation step was lengthened by an additional 4 minutes in 
order to make sure that the DNA was completely amplified.  
Each PCR experiment consisted of 86 test samples with the following 
controls: 2 known HPV-negative samples, 2 PCR reaction mixtures without sample 
DNA material, and a dilution series of human placental DNA (ranging from 100 pg to 
10 ng) serving as a positive control. 10µl of each PCR product was visualised by 
agarose gel electrophoresis. After agarose gel electrophoresis, positive controls 
should generate a signal of 209 base pairs and negative controls should not 
generate a signal. Special precautions were taken to minimize false-positive results 
in the PCR. Experiments were repeated if positive and negative controls did not give 
these expected results.  Samples showing a specific 209 base pair beta-globin PCR 
signal were considered beta-globin positive.  
All samples underwent PCR analysis to determine HPV positivity and high-
risk or low-risk HPV groups prior to individual HPV genotyping. Laboratory testing for 
HPV positivity was performed using a highly sensitive GP5+/6+ PCR assay followed 
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by hybridization of PCR products using an enzyme immunoassay (EIA) readout with 
two HPV oligoprobe cocktail probes that detect the following 44 HPV types: HPV6, 
11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 
57, 58, 59, 61, 64, 66, 67, 68, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 
(equivalent to CP8304), 82 (IS39 and MM4subtypes), 83 (equivalent to MM7), 84 
(equivalent to MM8), cand85, 86, cand89 (equivalent to CP6108) and JC9710 
(63;64).  
 A total of 40 cycles of PCR amplification with GP5+ and biotinylated GP6+ 
primers was performed following an initial 4 minute denaturation step at 94˚C. Each 
cycle consisted of a 20-second denaturation step at 94˚C, a 30-second primer 
annealing step at 38˚C, and a 80-second elongation step at 71˚C (65). The last 
elongation step was lengthened by an additional 4 minutes. 
 Each PCR experiment consisted of 86 test samples with the following 
controls: 2 known HPV-negative samples, 2 PCR reaction mixtures without sample 
DNA material, and a dilution series of known HPV 16-positive DNA (ranging from 
100 pg to 10 ng) serving as a positive control. This positive control was DNA derived 
from the cervical cancer cell line SiHa, which contained 1 to 2 copies of HPV 16 per 
cell. PCR runs or processing steps were repeated (<5%) if positive or negative 
controls did not give expected results.  
 PCR products were subsequently detected by EIA hybridization using two 
HPV oligoprobe cocktail probes to identify high-risk and low-risk HPV DNA (66). 
Each EIA run contained the 86 test samples, PCR positive and negative controls 
and 2 EIA positive controls, which were 2 biotinylated PCR products, one derived 
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from cloned HPV6 DNA plasmids for the low-risk HPV cocktail probe and the other 
derived from cloned HPV16 DNA plasmids for the high-risk HPV cocktail probe 
(63;66). 
 PCR products were captured on streptavidin-coated microwells and 
subsequently denatured with alkaline treatment and then hybridized to high-risk and 
low-risk oligonucleotide cocktail probes labelled with digoxigenin. 
Immunohistochemical staining with anti-digoxigenin polyclonal antibodies was 
performed and the optical density values at 405 nm were measured to determine if 
the cocktail probes bound (i.e. if high-risk or low-risk HPV DNA was present).  
Samples with an optical density at least 3 times the mean value of the 4 negative 
controls were considered GP5+/6+ PCR positive (66).  
HPV genotyping was subsequently performed on GP5+/6+ PCR positive PCR 
products by reverse line blot (RLB) hybridization (64;65). Oligoprobes specific for 
each individual HPV type were bound to negatively charged nylon membranes in 
parallel rows. PCR products were denatured and then pipetted into parallel channels 
that were perpendicular to the rows of oligoprobes. Hybridization was conducted at 
42˚C for 1 hour, followed by incubation of the nylon membrane with antibiotin 
conjugate, enhanced chemiluminescence detection and exposure to film.   
After hybridization of the PCR products, the sensitivity of the GP5+/6+ assay 
has been previously determined from reconstruction experiments to range from the 
femtogram level (approximately 70 copies of viral genome per 20,000 cells) for HPV 
types that were well amplified (e.g.HPV16 and 18) to the picogram level (700,000 
copies/20,000 cells) for HPV types that were less well amplified (e.g. HPV39 and 51) 
 24 
(67;68). The high specificity of RLB has also been demonstrated by the specific 
hybridization of the type-specific oglioprobes without cross-hybridization in validation 
experiments (65).   
For all analyses, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 
were considered high-risk types. HPV types detected by EIA but not by RLB 
genotyping were designated as HPVX, indicating a type, sub-type or variant not 
detectable with probes used for reverse line blot hybridization. Low-risk types 
included all other HPV types.   
 
HPV16/18/31 DNA viral load testing  
For men participating in the VIA sub-study, HPV DNA viral load testing was 
performed on penile exfoliated cell samples that contained HPV16, 18 or 31 using a 
real time PCR assay and a LightCycler instrument (Roche, Mannheim, Germany) 
(69). DNA extraction and purification were conducted according manufacturer 
instructions using 100 µl of the remaining cell suspensions. Real time PCR was 
performed on 100 ng of purified target DNA for each of the three specific HPV types 
(HPV16, 18 and 31). All samples were run twice and resulting values were 
averaged. Dilutions of cloned pHPV DNA were used to determine the standard curve 
for the HPV target. In order to calculate the number of copies per sample, the 
amount of HPV DNA in one femtogram was multiplied by the dilution factor and 
divided by the weight of the cloned pHPV viral genome. High HPV DNA viral load 
was defined as positive when HPV16, 18 or 31 specimen viral loads were >250 
copies per scrape in either the glans or shaft specimens (56). All other specimens 
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containing HPV16, 18 or 31 DNA were considered to have low HPV16/18/31 viral 
load.  This real time PCR assay was tested in validation experiments and found to 
be more accurate in assessing HPV16 viral load compared to GP5+6+/EIA assays 
(70). 
 
Visual inspection exams 
Consenting study participants were screened by a physician or clinical officer 
for the presence of penile lesions by visual inspection aided by a colposcope for 
magnification. The first visual inspection exam was conducted before the application 
of 3% acetic acid. A second visual inspection exam was performed 2-3 minutes after 
the application of a 3% acetic acid solution with saturated gauze to the penile shaft, 
glans, coronal sulcus, frenulum, and the outer and inner foreskin tissue for 
uncircumcised men. The second exam was conducted to differentiate HPV-
associated flat penile lesions, which are usually not visible without the application of 
3% acetic acid.  
Penile lesions were categorized as described previously (Chapter 2, Table 
2.2). The lesion type and location were recorded on a standardized form 
corresponding to the two anatomical sites: i. the external penile shaft, including the 
outer foreskin in uncircumcised men and from the base to the circumferential scar 
for circumcised men and ii. the glans, coronal sulcus, and frenulum, including the 
inner foreskin (which was retracted during this part of the exam) for uncircumcised 
men and the part distal to the circumferential scar in circumcised men.  
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For each visual inspection examination (before and after acetic acid 
application), two digital photographs were taken of the ventral and the dorsal side of 
the glans/coronal sulcus with the penile foreskin retracted for uncircumcised men. 
For quality control purposes, all photographs were also read in Amsterdam without 
knowledge of HPV data. The percent agreement between Kenya and Amsterdam 
readings were 83.5%, 80.1%, and 74.2% for flat penile lesions, papular lesions and 
pearly penile papules, respectively. Final outcome diagnoses were based on the 
readings by two independent observers in Amsterdam and in case of discrepancies 
(<10%) a consensus diagnosis was made to determine the final outcome. 
 
Statistical Methods 
Natural history of HPV infection 
Of the 1,102 men enrolled in the control arm of the RCT with HPV DNA 
results at baseline, 954 had an HPV result from the 12-month visit, of which 949 
remained uncircumcised until the 12-month visit and were included in subsequent 
statistical analyses. Men who were circumcised between the 12 and 24-month visits 
(n=39) contributed data until the visit date prior to circumcision (i.e. their 12-month 
visit). HPV prevalence at baseline and IRs for the first HPV type detected over the 
24-month follow-up period were estimated for individual HPV types and for groups of 
HPV types (any HPV, high-risk HPV and low-risk HPV). A prevalent HPV infection 
was defined as a HPV infection detected at baseline. An incident or acquired 
infection was defined as the detection of a type-specific HPV infection at either the 
12 or 24-month visit that was not detected at baseline.  
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For incidence analyses, individual subjects were the unit of analysis. The time 
at risk for an incident HPV infection was estimated from the date of the baseline visit 
until the time of the first HPV-positive result at the glans or shaft or until a participant 
was censored. Participants were censored on the date of their last visit prior to 
circumcision if they were circumcised before their 24-month visit or on the date of 
their last study visit if they remained HPV negative. IRs for each HPV type or HPV 
group were estimated only among participants who were negative for the given 
individual HPV type or group of types at baseline. Men with HPV infections of 
multiple HPV types were considered to have a high-risk HPV infection if one or more 
high-risk types were detected and a low-risk infection if only low-risk types were 
detected. Men with untyped HPV infections (i.e. HPVX) were excluded from 
analyses involving high-risk and low-risk HPV categorizations unless they had a 
high-risk HPV type detected. Incidence analyses were repeated stratified by 
anatomical site for each group of HPV types and HPV16, among participants who 
were negative for the particular HPV type or group of types at the given anatomical 
site.  
The 95% CIs for all IRs were estimated by modeling the number of incident 
HPV infections as a Poisson variable (36;71). Hazard ratios comparing IRs for i. 
high-risk versus low-risk HPV infections and ii. HPV infections in the glans versus 
the shaft were estimated using time in days and the Win-Lin-Weissfeld method to 
adjust for correlation within subjects (72).  
Given that each participant could have more than one HPV infection at a 
given time, the units of analysis for all persistence analyses were individual HPV 
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infections. Persistence of an incident HPV infection (i.e. incident persistence) was 
defined as repeat positivity for a type-specific HPV infection at the 12 and 24-month 
visits that was not detected at baseline. Only incident infections at the 12-month visit 
were included in the incident persistence analysis since it was unknown whether 
incident infections detected at the 24-month visit persisted after the end of follow-up. 
Persistence of a prevalent HPV infection (i.e. prevalent persistence) was defined as 
repeat positivity on two or more consecutive visits for a type-specific HPV infection 
detected at baseline. For each individual HPV type and group of types, i. the 
proportion of incident 12-month HPV infections that persisted until the 24-month visit 
and ii. the proportion of prevalent baseline HPV infections that persisted from 
baseline until at least the 12-month visit were calculated, stratified by anatomical 
site. HPV infections from 169 (17.8%) of the 949 participating men were excluded 
from only the incident persistence analysis if the participant did not have a 24-month 
HPV result (n=130) or was circumcised before the 24-month visit (n=39). HPVX 
infections were excluded from high-risk and low-risk HPV categorizations in all 
persistence analyses due to their unknown oncogenic status. For each group of HPV 
types, 95% CIs for incident and prevalent persistence were estimated using 
generalized estimating equations (GEEs) to account for correlation within subjects 
(72). Results did not differ substantially when pooling glans and shaft infections due 
to the low number of persistent HPV infections in the shaft (data not shown). 
The proportion of remaining prevalent HPV infections at the end of 24-month 
follow-up (i.e. proportion of HPV infections detected at all 3 visits) was estimated 
using the Kaplan-Meier method for the glans and shaft separately. The time at risk 
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for the detection of a cleared HPV infection was estimated from the date of the 
baseline visit until the time of the first HPV-negative result or until an infection was 
censored. Infections were censored on the visit date prior to circumcision for men 
who were circumcised before their 24-month visit or on the date of the last HPV-
positive result. Differences in time (in days) to detection of HPV clearance in the 
glans by HPV type (high-risk vs. low-risk) and by age group (≤19, 20-21, and ≥22 
years) were assessed using the Win-Lin-Weissfeld method to adjusted for 
correlation within subjects (72).  
Beta-globin positivity in the glans and shaft specimens was 56.9% and 35.9% 
at baseline, 69.7% and 45.9% at the 12-month visit, and 78.4% and 50.5% at the 24-
month visit. Reported analyses utilized HPV DNA data from all penile exfoliated cell 
specimens regardless of beta-globin positivity. Results did not differ substantially 
when analyses were restricted to beta-globin positive samples from both the glans 
and the shaft, except that persistence of incident HPV infections in the glans was 
slightly higher compared to analyses that included all samples. 
 
Risk factors of penile lesions  
Pearson’s χ2 and Fisher’s exact tests were used to assess differences in i. 
baseline risk factors between men participating in the VIA exam and all other men 
enrolled in the parent RCT; ii. 24-month risk factors between circumcised and 
uncircumcised men; and iii. flat penile lesion prevalence stratified by circumcision 
status. Prevalence odds ratios (ORs) and corresponding 95% CIs for potential risk 
factors of flat penile lesions were estimated via age-adjusted, univariate logistic 
 30 
regression models. A multivariate logistic regression model was used to estimate the 
OR for flat penile lesions and HPV DNA positivity adjusted for age and male 
circumcision status since these variables were believed a priori to be potential 
confounders. Analyses were repeated for papular lesions and pearly penile papule 
outcomes.  
HPV infections with multiple HPV types were considered high-risk if one or 
more high-risk HPV types were detected. Low-risk types included all other known 
HPV types. Men with untyped HPV infections (i.e. HPVX) were excluded from 
analyses involving high-risk and low-risk HPV categorizations unless they also had a 
known high-risk HPV type detected.     
Of 151 circumcised men who consented to VIA exams, 8 (5.3%) were 
originally assigned to the control arm of the trial but were circumcised before their 
24-month visit and therefore excluded from analyses. Results were similar with the 
inclusion of these 8 men. Beta-globin positivity was 87.2% in the glans specimens 
and 73.6% in the shaft specimens. Reported analyses utilized HPV DNA data from 
all penile exfoliated cell specimens regardless of beta-globin positivity. Results did 
not differ substantially when analyses were restricted to beta-globin positive glans 
and shaft samples.  
  
 
3
1
 
Table 3.1 Inclusion and exclusion criteria for a randomized controlled trial of male circumcision conducted in  
Kisumu, Kenya (6). 
 
Inclusion Criteria Exclusion Criteria 
 
Uncircumcised Foreskin covering less than half of the glans 
 
HIV negative Hemophilia or other bleeding disorder 
 
Sexually active within the past 12 months High prothrombin time index 
 
Aged 18-24 years Hypospadias 
 
Resident of Kisumu, Kenya Other medical condition contraindicating surgery 
 
Not planning to move in the next 2 years Absolute indication for circumcision 
 
Blood hemoglobin ≥90 g/L   
 
Willing and able to give informed consent 
  
 
 
  
 
 
 
 
 
CHAPTER 4. 
INCIDENCE AND PERSISTENCE OF PENILE HUMAN PAPILLOMAVIRUS 
INFECTION AMONG UNCIRCUMCISED MEN FROM KENYA 
 
Abstract    
Background: Data on the natural history of HPV infection in men are limited, 
especially from less developed regions including Africa.   
Methods: Penile exfoliated cell specimens were collected at the baseline, 12 
and 24-month visits from the glans/coronal sulcus and shaft of men enrolled in the 
control arm of a RCT of male circumcision in Kenya between 2002-2007. All 
participants were HIV seronegative and aged 17-24 years at baseline. Specimens 
were tested with GP5+/6+ PCR to detect 44 HPV types.  
Results: Among 949 uncircumcised participants, median follow-up time was 
24.2 months (range 11.6-30.4). The IR of any HPV infection was 24.3/1,000 person-
months. The incidence of HPV infection was higher for high versus low-risk HPV 
(hazard ratio=1.7; 95% CI: 1.4-2.1) and in glans versus shaft (hazard ratio=2.1; 95% 
CI: 1.8-2.5). The proportion of incident glans HPV infections that persisted from the 
12 to 24-month visits was 18.3% (95% CI: 15.0-22.3). The percentage of prevalent 
HPV infections in the glans that persisted from baseline until at least the 12-month 
visit was 13.5% (95% CI: 11.1-16.3). HPV clearance was similar for high-risk versus 
low-risk infections and by age group. 
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Conclusions: The natural history of HPV infection among men may be 
different than that previously described for women, with a relatively high incidence of 
penile HPV infection found among men. Differences in patterns of high and low-risk 
HPV clearance between men and women may also exist. 
 
Introduction 
Carcinogenic HPV infections are necessary for the development of ICC, and 
are also considered etiologic agents of other non-cervical cancers among both men 
and women (1-4). While many previous studies have described HPV infection 
among women, data on the prevalence and natural history of HPV infection among 
men are relatively limited (5). A greater understanding of HPV infection among men 
is needed given that men are an important factor for increased risk of HPV infection 
and ICC in their female sexual partners (7), and since HPV infection is associated 
with penile and anal cancers among men (2;3).   
Few prospective, follow-up studies have been published on HPV infection 
among men from North America, Europe and Africa (36-44). The IR of penile HPV 
infections for the first overall HPV type detected has ranged from 17.9 to 34.9/1,000 
person-months (36;37;39). Type-specific persistence of HPV infection over one year 
has been found to range between  25-30%  among HPV-positive men (36;37). Data 
are especially needed on the acquisition and persistence of HPV infection among 
men in less-developed geographical regions including sub-Saharan Africa, where 
the incidence of ICC is among the highest worldwide (8;9).  
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The aim of this study was to characterize the type-specific incidence and 
persistence of HPV infection over a 24-month period among 949 uncircumcised men 
participating in the control arm of a RCT of male circumcision in Kisumu, Kenya.  
 
Methods 
Study population and enrolment 
Uncircumcised men were screened between February 4, 2002 and 
September 6, 2005 in Kisumu, Kenya to participate in a RCT of male circumcision 
(6). The primary aim of the RCT was to determine the effectiveness of male 
circumcision in reducing HIV incidence. In brief, inclusion criteria included being 
uncircumcised, aged 18-24 years, HIV seronegative, sexually active, and having 
blood hemoglobin ≥90 g/L. Study participants were recruited from STI clinics, 
workplaces, and community organizations. The study protocol was approved by the 
Institutional Review Boards of the Universities of Illinois at Chicago, Manitoba, 
Nairobi, and North Carolina; RTI International; and the VU University Medical 
Center. 
 
Specimen collection  
After undergoing informed consent, participants were administered a 
standardized questionnaire on sociodemographic characteristics and sexual 
behavior by a trained male interviewer. Penile exfoliated cells were collected for 
HPV DNA detection at the baseline, 12 and 24-month medical visits. At each visit, 
specimens were taken from two anatomical sites: i. shaft and external foreskin tissue 
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(shaft specimen) and ii. the glans, coronal sulcus and inner foreskin tissue (glans 
specimen) using prewetted Type 3 Dacron swabs and placed in separate conical 
tubes (18).  
Penile cell samples were placed in individual 15-mL centrifuge tubes 
containing 2-mL 0.01 mol/L Tris-HCl, 7.4 pH, buffer, and processed on the day of 
collection at the UNIM (Universities of Nairobi, Illinois, and Manitoba) clinic 
laboratory by centrifugation at high speed (maximum, 3000g) for 10 minutes. Excess 
Tris-HCl buffer was discarded using a Pasteur pipette, and the remaining cell pellet 
was resuspended in the same volume of 0.01 mol/L Tris-HCl buffer, and vortexed. 
Diluted cell pellets were then frozen at -75°C. All samples were sent using a dry 
shipper to the Department of Pathology, VU University Medical Center, Amsterdam, 
the Netherlands, for HPV DNA testing. 
 
HPV DNA and STI testing 
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system 
(Hamilton, Germany) according to manufacturers’ instructions. Presence of human 
DNA was evaluated by beta-globin specific PCR, followed by agarose gel 
electrophoresis. HPV positivity was assessed by GP5+/6+ PCR followed by 
hybridisation of PCR products using an EIA readout with two HPV oligoprobe 
cocktail probes that, together, detect 44 HPV types: HPV6, 11, 16, 18, 26, 30, 31, 
32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64, 66, 
67, 68, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 
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(IS39 and MM4subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), cand85, 
86, cand89 (equivalent to CP6108) and JC9710. Subsequent HPV genotyping was 
performed by RLB hybridisation of PCR products, as described previously in 
Chapter 3 (64;65).  
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered 
high-risk types. HPV types detected by EIA but not by RLB genotyping were 
designated as HPVX, indicating a type, sub-type or variant not detectable with 
probes used for RLB hybridization. Low-risk types included all other HPV types.  
Urine samples were tested for N. gonorrhea and C. trachomatis infections by 
PCR-based methods (Roche Diagnostics) at baseline. Serum specimens were 
tested for HSV-2 antibody (Kalon) and for HIV antibody using two rapid tests 
(Determine, Abbott Diagnostic Division, Hoofddorp, Netherlands; and Unigold, Trinity 
Biotech, Wicklow, Ireland) and confirmed by double ELISA (Adaltis Inc, Montreal, 
Canada; Trinity Biotech, Wicklow, Ireland) at the University of Nairobi.   
 
Statistical methods 
Of the 1,102 men enrolled in the control arm of the RCT with HPV DNA 
results at baseline, 954 had an HPV result from the 12-month visit, of which 949 
remained uncircumcised until the 12-month visit and were included in subsequent 
statistical analyses. Men who were circumcised between the 12 and 24-month visits 
(n=39) contributed data until the visit date prior to circumcision (i.e. their 12-month 
visit). HPV prevalence at baseline and IRs for the first HPV type detected over the 
24-month follow-up period were estimated for individual HPV types and for groups of 
HPV types (any HPV, high-risk HPV and low-risk HPV). A prevalent HPV infection 
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was defined as a HPV infection detected at baseline. An incident or acquired 
infection was defined as the detection of a type-specific HPV infection at either the 
12 or 24-month visit that was not detected at baseline. 
For incidence analyses, the individual subject was the unit of analysis. The 
time at risk for an incident HPV infection was estimated from the date of the baseline 
visit until the time of the first HPV-positive result at the glans or shaft or until a 
participant was censored. Participants were censored on the date of their last visit 
prior to circumcision if they were circumcised before their 24-month visit or on the 
date of their last study visit if they remained HPV negative. IRs for each HPV type or 
HPV group were estimated only among participants who were negative for the given 
individual HPV type or group of types at baseline. Men with HPV infections of 
multiple HPV types were considered to have a high-risk HPV infection if one or more 
high-risk types were detected and a low-risk HPV infection if only low-risk types were 
detected. Men with untyped HPV infections (i.e. HPVX) were excluded from 
analyses involving high-risk and low-risk HPV categorizations unless they had a 
high-risk HPV type detected. Incidence analyses were repeated stratified by 
anatomical site for each group of HPV types and HPV16, among participants who 
were negative for the particular HPV type or group of types at the given anatomical 
site.  
The 95% CIs for all IRs were estimated by modeling the number of incident 
HPV infections as a Poisson variable (36;71). Hazard ratios comparing IRs for i. 
high-risk versus low-risk HPV infections and ii. HPV infections in the glans versus 
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the shaft were estimated using time in days and the Win-Lin-Weissfeld method to 
adjust for correlation within subjects (72).  
Given that each participant could have more than one HPV infection at a 
given time, the units of analysis for all persistence analyses were individual HPV 
infections. Persistence of incident HPV infection (i.e. incident persistence) was 
defined as repeat positivity for a type-specific HPV infection at the 12 and 24-month 
visits that was not detected at baseline. Only incident infections at the 12-month visit 
were included in the incident persistence analysis since it was unknown whether 
incident infections detected at the 24-month visit persisted after the end of follow-up. 
Persistence of a prevalent HPV infection (i.e. prevalent persistence) was defined as 
repeat positivity on two or more consecutive visits for a type-specific HPV infection 
detected at baseline. For each individual HPV type and group of types, i. the 
proportion of incident 12-month HPV infections that persisted until the 24-month visit 
and ii. the proportion of prevalent baseline HPV infections that persisted from 
baseline until at least the 12-month visit were calculated, stratified by anatomical 
site. HPV infections from 169 (17.8%) of the 949 participating men were excluded 
from only the incident persistence analysis if the participant did not have a 24-month 
HPV result (n=130) or was circumcised before the 24-month visit (n=39). HPVX 
infections were excluded from high-risk and low-risk HPV categorizations in all 
persistence analyses due to their unknown oncogenic status. For each group of HPV 
types, 95% CIs for incident and prevalent persistence were estimated using GEEs to 
account for correlation within subjects (72). Results did not differ substantially when 
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pooling glans and shaft infections due to the low number of persistent HPV 
infections in the shaft (data not shown). 
The proportion of remaining prevalent HPV infections at the end of 24-month 
follow-up (i.e. proportion of HPV infections detected at all 3 visits) was estimated 
using the Kaplan-Meier method for the glans and shaft separately. The time at risk 
for the detection of a cleared HPV infection was estimated from the date of the 
baseline visit until the time of the first HPV-negative result or until an infection was 
censored. Infections were censored on the visit date prior to circumcision for men 
who were circumcised before their 24-month visit or on the date of the last HPV-
positive result. Differences in time (in days) to detection of HPV clearance in the 
glans by HPV type (high-risk vs. low-risk) and by age group (≤19, 20-21, and ≥22 
years) were assessed using the Win-Lin-Weissfeld method to adjusted for 
correlation within subjects (72).  
Beta-globin positivity in the glans and shaft specimens was 56.9% and 35.9% 
at baseline, 69.7% and 45.9% at the 12-month visit, and 78.4% and 50.5% at the 24-
month visit. Reported analyses utilized HPV DNA data from all penile exfoliated cell 
specimens regardless of beta-globin positivity. Results did not differ substantially 
when analyses were restricted to beta-globin positive samples. 
 
Results 
  The median age of the 949 included men was 20 years (range 17-24) at 
baseline (Table 4.1).  The median numbers of reported lifetime female partners and 
female partners in the year prior to enrolling in the RCT were 4 (range 1-86) and 2 
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(range 0-28), respectively. Only 1 (0.1%) participant reported a male sexual partner. 
Most men did not live with their sexual partner (93.9%), had at least a secondary 
education (63.0%) and no source of income (63.9%). Approximately one-third 
(34.8%) of men reported never using a condom in the past 6 months. The 
prevalence of HSV-2 seropositivity was 27.1%, with laboratory-diagnosed C. 
trachomatis (4.4%) and N. gonorrhea (1.3%) infections being less common.  
  Baseline prevalence of HPV infection was 49.7%, with multiple HPV 
infections found among 28.6% of participants (Table 4.2). High-risk and low-risk 
HPV types were detected in 35.8% and 10.1% of participants, respectively. The six 
most common individual HPV types were HPV16 (9.2%), 56 (6.8%), 67 (5.6%), 52 
(5.6), 66 (5.1%) and 45 (5.0%) within single or multiple infections. All other known 
HPV types detected had a prevalence of less than 5%. HPVX infections were 
detected in 5.4% of participants. 
  The median time follow-up time was 24.2 months (range 11.6-30.4). The 
median time between study visits was 12.2 months (range 10.4-17.2) from the 
baseline to 12-month visits and 12.0 months (range 7.0-17.1) from the 12 to 24-
month visits. 
 
Incidence analysis  
  The IR of any HPV infection was 24.3/1,000 person-months for the first HPV 
type detected at either the glans or the shaft (Table 4.2). Incident infections of 
multiple HPV types were common (14.1/1,000 person-months). The IR of high-risk 
HPV was higher compared to low-risk HPV (hazard ratio=1.7; 95% CI: 1.4-2.1). The 
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four individual HPV types with the highest incidence were HPV16 (IR=5.5/1,000 
person-months), JC9710 (IR=3.7/1,000 person-months), HPV56 (IR=3.6/1,000 
person-months) and HPV35 (3.5/1,000 person-months). All other HPV types had an 
incidence less than 3.5/1,000 person-months. 
  The incidence of any HPV infection was higher in the glans than in the shaft 
(hazard ratio=2.1; 95% CI: 1.8-2.5) (Table 4.3). The incidence of high-risk and low-
risk infections in the glans were 16.2 and 9.6/1,000 person-months respectively, with 
lower corresponding rates for high-risk and low-risk HPV infections in the shaft (6.2 
and 4.6/1,000 person-months, respectively). Incident infections of multiple HPV 
types were also more common in the glans compared to the shaft (hazard ratio=3.2; 
95% CI: 2.5-4.0). 
  
Persistence of incident HPV infections 
  A total of 550 incident HPV infections were detected in the glans at the 12-
month visit, of which 100 (18.2%) persisted until the 24-month visit (Table 4.4). The 
proportions of high-risk and low-risk incident HPV infections that persisted from the 
12 to 24-month visits were 16.7% (n=43) and 21.0% (n=57), respectively. Among the 
high-risk types, HPV51 was most persistent with 5 (27.8%) of 18 incident infections 
persisting until the 24 month visit, followed by HPV56 (23.1%), HPV16 (20.0%), 
HPV59 (20.0%) and HPV66 (20.0%).   
  A total of 192 incident HPV infections were detected in the shaft at the 12-
month visit, of which 9 (4.7%) persisted until the 24-month visit. Three (3.4%) of 88 
incident high-risk infections and 6 (6.5%) of 92 incident low-risk infections persisted. 
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Persistence/clearance of prevalent HPV infections 
  A total of 944 HPV infections were detected in the glans at baseline (Table 
4.4), with 13.5% persisting until at least the 12-month visit. The proportions of high-
risk and low-risk prevalent HPV infections that persisted until the 12-month visit were 
14.4% and 13.4%, respectively. Among the high-risk prevalent HPV types, the 
highest proportions of persistence were found for HPV56 (22.4%) and HPV51 
(21.2%). A total of 26 (3.2%) of 805 prevalent HPV infections with a 24-month result 
persisted from the baseline to 24-month visits. There did not appear to be a 
difference in the time until detection of clearance by HPV type during the 24-month 
follow-up (Figure 4.1) (hazard ratio=0.91; 95% CI: 0.81-1.04 for high vs. low-risk 
infections). The cumulative probability of HPV persistence was also similar across 
age groups (Figure 4.2). Compared to younger men (aged ≤19), the cumulative 
probability of persistence of HPV infections in the glans of men aged 20-21 and ≥22 
clearance were similar (hazard ratios=0.9; 95% CI: 0.7-1.2 and 0.9; 95% CI: 0.7-1.2, 
respectively).   
  Of the 284 HPV infections detected in the shaft at baseline, only 4 (1.4%) 
infections persisted until the 12-month visit and 2 (0.7%) persisted until the 24-month 
visit. 
 
Discussion 
  Incident HPV infections were common among men from Kenya with an IR of 
almost 25/1,000 person-months. The incidence of high-risk HPV infections in the 
glans was especially high compared to low-risk infections and HPV infections in the 
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shaft. The proportion of persistent incident HPV infections in the glans (18.2%) was 
slightly higher compared to the persistence of prevalent HPV infections in the glans 
(13.5%). The persistence of both incident and prevalent infections in the shaft over 
12 months was low (<5%). Detection of HPV clearance in the glans throughout 
follow-up was similar for high-risk and low-risk prevalent infections and did not differ 
by age.     
  This is the largest follow-up study of HPV infection, to our knowledge, among 
uncircumcised men to date and the first to characterize the natural history of low-risk 
HPV infections among men from sub-Saharan Africa. A sensitive GP5+/6+ PCR 
assay was used to detect a wide range of HPV types in a central laboratory allowing 
for comparisons with natural history studies among women. Separate HPV testing 
for glans and shaft specimens also allowed for stratified analyses by anatomical site.   
  The IR of 24.3/1,000 person-months found in our study is consistent with 
previously reported IR estimates among men ranging from 17.9/1,000 person-
months among military men from Mexico to 34.9/1,000 person-months among male 
university students in the United States (36;37;39). Our IR estimate for high-risk 
HPV infection in the glans (16.2/1,000 person-months), was lower than the 
corresponding IR in the glans among HIV-negative, married men aged 15-49 
participating in the control arm of an RCT of male circumcision in Uganda 
(24.5/1,000 person-months) (43). Compared to our study, analyses in the Ugandan 
study utilized a shorter interval between study visits, which may help explain the 
disparity in the observed IRs. The IR of high-risk HPV infection among HIV-negative 
women from Uganda (7.2/1,000 person-months) (73) and Brazil (6.1/1,000 person-
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months) (48) was lower than the rates observed among men in our study and in the 
Uganda RCT, indicating that men may be more likely to acquire HPV infections 
compared to women.  
  HPV16, the most prevalent HPV type (9.2%), had the highest incidence in this 
population with a rate of 5.5/1,000 person-months. A high incidence of HPV16 has 
also been reported in other studies among both men (36;38;39) and women (73). 
The high rate of acquisition of HPV16 has a clear implication for cancer risk among 
men and their sexual partners as HPV16 is the most common HPV type found in 
penile cancer among men (2), cervical, vulvar and vaginal cancers among women 
(1;19) and anal and oropharyngeal cancers among both sexes (3;4). 
  HPV IRs among men in our study were higher in the glans compared to the 
shaft (hazard ratio=2.1; 95% CI: 1.8-2.5). These results are in contrast to the 
findings of a study of 240 men from the United States (39) wherein the cumulative 
probability of incident HPV infections did not differ by anatomical site. Over 75% of 
the latter study population was circumcised and so there may be a larger disparity in 
HPV acquisition by penile site among uncircumcised men.   
  Given that a participant could have more than one HPV infection at a given 
time, we analyzed persistence of both incident and prevalent HPV infections using 
the individual HPV infection as the unit of observation. The proportions of men who 
had at least one type-specific persistent HPV infection in the glans were 29.3% and 
22.3% for incident and prevalent HPV infections, respectively. These proportions are 
expectedly higher than the percentages of incident and prevalent HPV infections in 
the glans that persisted (18.2 and 13.5%, respectively) given that men with multiple 
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HPV infections had more than one opportunity to be defined as having a persistent 
HPV infection.  
  HPV clearance was similar for both high-risk and low-risk HPV infections and 
among age groups. These findings are similar to those of a previous study in the 
United States of 290 men aged 18-49 that found no difference in the median time to 
clearance for high-risk and low-risk HPV infections and no clear association between 
HPV clearance and age group (36). In contrast, natural history studies among 
women have generally found a lower clearance of high-risk HPV infections 
compared to low-risk types (47;48). 
The 12-month interval between each visit was a limitation of this study. Two 
previous studies reported a median duration of clearance among men of 3-6 months 
(36;42). Participants in our study could have therefore acquired a new HPV infection 
and cleared it before the subsequent follow-up visit. Incident HPV infections could 
have also occurred before they had the opportunity to be detected at the 12 or 24-
month follow-up visits. Thus, IRs for the first HPV type detected likely underestimate 
the actual IR of HPV infection. In our analysis, the incidence of detected HPV 
infections ranged from 0.05/1,000 person-months for HPV44 to 5.5/1,000 person-
months for HPV16. Reanalyzing our data assuming a new HPV infection was 
acquired at the midpoint of the interval as in one recent study (43), the IR of HPV 
infections increased slightly ranging from 0.1 to 7.7/1,000 person-months for HPV44 
and HPV16, respectively.  Further, we were also unable to determine if a participant 
had a persistent HPV infection, or cleared and re-acquired another HPV infection of 
the same type within the 12-month interval, which may have led to an overestimation 
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of HPV persistence over a 12-month period.  A reliable median duration of clearance 
could also not be estimated due to the length of the interval between study visits. 
The generalizability of our findings may be limited, given that included 
participants were a select population of uncircumcised men, who met eligibility 
criteria for an RCT that entailed circumcision (e.g. age 18-24 years, HIV 
seronegative at enrolment). Uncircumcised men may be more likely to acquire (43) 
and less likely to clear HPV infections than circumcised men (42;43), thus our 
findings should be compared to those of circumcised populations with caution. It has 
been suggested that age may be a proxy for sexual behavior and immune response 
among women (74-76). The relatively small age range of included participants in this 
study, however limited our assessment of HPV clearance by age among men.  
  In conclusion, we found a high incidence of high-risk HPV in the glans but no 
difference in HPV clearance between high-risk and low-risk HPV infections or by 
age. The IR of HPV infection among men appears higher than in women. 
Differences in patterns of high-risk and low-risk HPV clearance between men and 
women may also exist. Future studies using similar study designs are needed to 
confirm potential differences in the natural history of HPV between men and women 
by investigating comparable populations of both men and women.    
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Table 4.1 Baseline characteristics of 949 uncircumcised men from Kisumu,  
Kenya 
 
Variable   
Median (range) 
Age (years)*  20 (17-24)  
Lifetime number of female sexual partners    4 (1-86)  
Number of female partners in last 12 months    2 (0-28)   
n (%) 
Marital Status 
     Not living with partner 888 (93.9) 
     Living with partner  58 (6.1) 
     Missing 3 
Education 
     Secondary or tertiary 598 (63.0) 
     Primary or none 351 (37.0) 
Employment Status 
     No income  606 (63.9) 
     Income  343 (36.2) 
Condom Use in last 6 months 
     >50% 223 (26.6) 
     ≤50% 323 (38.5) 
     Never   292 (34.8) 
     Missing 111 
HSV-2 seropositive 
     Yes 248 (27.1) 
     No 668 (72.9) 
     Missing 33 
Presence of C. trachomatis 
     Yes   41 (4.4) 
     No 898 (95.6) 
     Missing 10 
Presence of N. gonorrhea 
     Yes   12 (1.3) 
     No 927 (98.7) 
     Missing 10 
HSV: Herpes simplex virus 
*The study inclusion criteria required participants be aged 18-24 years; there 
was one protocol violation resulting in one 17 year-old included in this study 
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Table 4.2 Prevalence and incidence of human papillomavirus infection among 949 
uncircumcised men in Kisumu, Kenya 
 
HPV type 
Baseline 
Prevalence, 
% 
Incident 
infections, n 
Subjects 
at risk, n 
Person- 
months IR*  (95% CI) 
Any HPV 49.7 218 477  8,970.7 24.3 (21.2, 27.8) 
Multiple† 
 
28.6 196 678 13,945.2 14.1 (12.2, 16.1) 
 HR HPV† 35.8 219 609 12,314.6 17.8 (15.5, 20.3) 
16 9.2 104 862 18,815.8 5.5 (4.5, 6.7) 
18 3.3 47 918 20,314.1 2.3 (1.7, 3.1) 
31 3.6 35 915 20,359.9 1.7 (1.2, 2.4) 
33 1.8 23 932 20,799.7 1.1 (0.7, 1.7) 
35 3.3 71 918 20,165.5 3.5 (2.7, 4.4) 
39 1.8 28 932 20,754.7 1.3 (0.8, 1.9) 
45 5.0 32 902 20,038.8 1.6 (1.1, 2.3) 
51 4.2 45 909 20,173.3 2.2 (1.6, 3.0) 
52 5.4 42 898 19,975.0 2.1 (1.5, 2.8) 
56 6.8 70 884 19,480.8 3.6 (2.8, 4.5) 
58 4.2 41 909 20,223.5 2.0 (1.5, 2.8) 
59 4.3 33 908 20,206.1 1.6 (1.1, 2.3) 
66 5.1 51 901 19,886.4 2.6 (1.9, 3.4) 
68 1.2 10 938 21,047.4 0.5 (0.2, 0.9) 
LR HPV† 10.1 178 802 17,163.3 10.4 (8.9, 12.0) 
6 3.3 52 918 20,310.3 2.6 (1.9, 3.4) 
11 1.9 28 931 20,751.0 1.3 (0.9, 2.0) 
26 1.4 15 936 20,943.9 0.7 (0.4, 1.2) 
30 1.6 18 934 20,901.4 0.9 (0.5, 1.4) 
32 1.4 14 936 20,983.4 0.7 (0.4, 1.1) 
34 0.1 1 948 21,299.3 0.0 (0.0, 0.3) 
40 3.6 45 915 20,337.1 2.2 (1.6, 3.0) 
42 4.8 62 903 19,895.7 3.1 (2.4, 4.0) 
43 3.9 42 912 20,256.6 2.1 (1.5, 2.8) 
44 0.0 1 949 21,324.1 0.0 (0.0, 0.3) 
53 1.1 0 939 21,092.5 
54 1.1 4 939 21,055.8 0.2 (0.1, 0.5) 
55 1.4 14 936 20,941.9 0.7 (0.4, 1.1) 
67 5.6 58 896 19,789.8 2.9 (2.2, 3.9) 
69 0.7 21 942 21,005.0 1.0 (0.6, 1.5) 
70 2.3 36 927 20,598.0 1.7 (1.2, 2.4) 
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Table 4.2 continued 
HPV type 
Baseline 
Prevalence, 
% 
Incident 
infections, n 
Subjects 
at risk, n 
Person- 
months IR*  (95% CI) 
72 0.8 9 941 21,103.4 0.4 (0.2, 0.8) 
73 1.4 27 936 20,881.1 1.3 (0.9, 1.9) 
81 3.2 29 919 20,441.8 1.4 (1.0, 2.0) 
82 0.6 15 943 21,151.7 0.5 (0.4, 1.1) 
83 1.8 28 932 20,688.1 1.4 (0.9, 2.0) 
84 0.3 6 946 21,226.6 0.3 (0.1, 0.6) 
85 0.2 12 947 21,179.3 0.6 (0.3, 1.0) 
86 0.0 12 949 21,276.7 0.6 (0.3, 1.0) 
89 2.0 20 930 20,691.3 1.0 (0.6, 1.5) 
JC9710 4.1 74 910 19,983.4 3.7 (2.9, 4.6) 
X   5.4   55 898 19,773.8 2.8 (2.1, 3.6) 
HPV: Human papillomavirus; HR: high risk; LR: low risk; IR: incidence rate; CI: confidence interval 
Note: HPV57, 61, 64, 71 were not detected at baseline nor during follow-up 
*Incidence rate per 1,000 person-months for the first type detected in the glans or shaft 
†
Multiple HPV included >1 HPV type. Infections with multiple HPV types were considered high-risk if 
one or more HR HPV types were detected.  All other multiple infections were considered LR types 
unless they included HPVX. 
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Table 4.3 Incidence of human papillomavirus infection stratified by anatomical site among 949 uncircumcised  
men from Kisumu, Kenya 
 
HPV type‡ 
Incident HPV 
infections in 
glans, n IR (95% CI)*  
Incident HPV 
infections in 
shaft, n IR (95% CI)*  
Hazard Ratio 
(95% CI)† 
   
Any HPV 217 21.9 (19.1, 25.0)  181 11.1 (9.5, 12.8)  2.1 (1.8, 2.5) 
Multiple   182 12.4 (10.6, 14.3)  77 3.9 (3.1, 4.9)  3.2 (2.5, 4.0) 
HR HPV 211 16.2 (14.0, 18.5)  113 6.2 (5.1, 7.5)  2.7 (2.2, 3.3) 
LR HPV 167 9.6 (8.2, 11.1)  90 4.6 (3.7, 5.6)  2.1 (1.7, 2.7) 
HPV16 83 4.3 (3.5, 5.3)  45 2.2 (1.6, 2.9)  2.0 (1.4, 2.7) 
HPV: Human papillomavirus; HR: high risk; LR: low risk; IR: incidence rate; CI: confidence interval 
*IR=incidence per 1,000 person-months 
†
Hazard ratio comparing glans versus shaft 
‡
Multiple HPV included >1 HPV type. Infections with multiple HPV types were considered high-risk if one or more HR HPV 
types were detected. All other multiple infections were considered LR unless they included HPVX.
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Table 4.4 Persistence of 550 incident human papillomavirus infections detected at the 12-
month visit and 944 prevalent HPV infections detected at baseline in the glans of men from 
Kisumu, Kenya 
 
HPV type 
Incident 
Infections  
Incident Persistent 
HPV Infections* 
Prevalent 
Infections 
Prevalent Persistent 
HPV Infections† 
N n % (95% CI) N n % (95% CI) 
Any HPV 550 100 18.2 (15.0, 22.3) 944 127 13.5 (11.1, 16.3) 
HR HPV 257 43 16.7 (12.6, 22.2) 487 70 14.4 (11.2 18.4) 
16 35 7 20.0 (8.4, 36.9) 72 12 16.7 (8.9, 27.3) 
18 19 2 10.5 (0.8, 22.8) 26 4 15.4 (4.4, 34.9) 
31 13 2 15.4 (1.9, 45.4) 27 5 18.5 (6.3, 38.1) 
33 8 1 12.5 (0.3, 52.7) 15 3 20.0 (4.3, 48.1) 
35 32 6 18.8 (7.2, 36.4) 29 1 3.4 (0.1, 17.8) 
39 14 2 14.3 (1.7, 42.8) 15 3 20.0 (4.3, 48.1) 
45 16 1 6.3 (0.2, 30.2 39 3 7.7 (1.6, 20.9) 
51 18 5 27.8 (9.7, 53.5) 33 7 21.2 (9.0, 38.9) 
52 15 1 6.7 (0.2,3.2) 46 4 8.7 (2.4, 20.8) 
56 26 6 23.1 (9.0, 43.6) 58 13 22.4 (12.5, 35.3) 
58 15 1 6.7 (0.01,31.9) 39 7 17.9 (7.5, 33.5) 
59 15 3 20.0 (4.3, 48.1) 36 5 13.9 (4.7, 29.5) 
66 30 6 20.0 (7.7, 38.6) 42 3 7.1 (1.5,19.5)  
LR HPV 272 57 21.0 (16.5, 26.6) 424 57 13.4 (10.4, 17.3) 
6 19 7 36.8 (16.3, 61.6) 28 3 10.7 (2.3, 28.2) 
11 11 1 9.1 (0.2, 41.3) 14 2 14.3 (1.7, 42.8) 
26 8 1 12.5 (0.3, 52.7) 13 0 0.0 (0.0, 24.7) 
32 2 0 0.0 (0.0, 84.2) 13 2 15.4 (1.9, 45.4) 
40 17 4 23.5 (6.8, 49.9) 31 8 25.8 (11.9, 44.6) 
42 27 8 29.6 (13.8, 50.2) 42 5 11.9 (4.0, 25.6) 
43 16 2 12.5(1.6, 38.3) 35 5 14.3 (4.8, 30.3) 
55 6 0 0.0 (0.0, 45.9) 13 1 7.7 (2.0, 36.0) 
67 23 8 34.8 (16.4, 57.3) 47 10 21.3 (10.7, 35.7) 
69 11 3 27.3 (6.0, 61.0) 7 2 28.6 (3.7, 71.0) 
70 15 1 6.7 (0.2, 31.9) 20 6 30.0 (11.9, 54.3) 
72 2 1 50.0 (1.3, 98.7) 8 0 0.0 (0.0, 36.9) 
73 13 2 15.4 (1.9, 45.4) 13 0 0.0 (0.0, 24.7) 
81 15 2 13.3 (1.7, 40.5) 25 3 12.0 (2.5, 31.2) 
83 15 1 6.7(0.2, 31.0) 15 1 6.7 (0.2, 31.9) 
85 7 4 57.1 (18.4, 90.1) 2 1 50.0 (0.1, 98.7) 
86 4 2 50.0 (6.8, 93.2) 0 0 
89 12 4 33.3 (9.9, 65.1) 18 2 11.1 (1.4, 34.7) 
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Table 4.4 continued 
HPV type 
Incident 
Infections  
Incident Persistent 
HPV Infections* 
Prevalent 
Infections 
Prevalent Persistent 
HPV Infections† 
N n % (95% CI) N n % (95% CI) 
JC9710 32 6 18.8 (7.2, 36.4) 39 6 15.4 (58.6, 30.5) 
X‡ 21 2 33 1 
HPV: Human papillomavirus; HR: high risk; LR: low risk;  
Note: No incident infections at the 12-month visit, nor prevalent infections at baseline were detected 
at the glans for low-risk HPV34, 44, 57, 61, 64 or 71. HPV86 was not detected at baseline. No 
incident or prevalent persistent HPV infections were detected for HPV68, 30, 53, 54, 82, or 84. 
*Defined as repeat positivity for a type-specific HPV infection at the 12 and 24-month follow-up visits 
that was not present at baseline. 
†
Defined as repeat positivity on two or more consecutive visits for a type-specific HPV infection 
present at baseline. 
‡
HPVX infections were excluded from HR and LR categorizations due to their unknown oncogenic 
status. 2 incident persistent and 1 prevalent persistent HPVX infections were excluded from the any 
HPV category since type-specificity of persistent HPVX infections could not be determined.  
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Figure 4.1 Kaplan-Meier curves for the proportion of prevalent high-risk human 
papillomavirus (HPV) infections (dotted line) versus low-risk HPV infections (solid line) 
remaining positive through follow-up. High-risk types included HPV16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66, and 68. Low-risk types included HPV6, 11, 26, 30, 32, 34, 40, 42, 
43, 44, 53, 54, 55, 57, 61, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, cand85, 86, cand89 
and JC9710.     
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Figure 4.2 Kaplan-Meier curves for the proportion of prevalent human papillomavirus (HPV) 
infections remaining by age group (aged ≤19 years = solid line; 20-21 years = dashed line 
( ); ≥22 years = dashed line ( ).      
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CHAPTER 5. 
MALE CIRCUMCISION IS ASSOCIATED WITH A LOWER PREVALENCE OF 
HUMAN PAPILLOMAVIRUS-ASSOCIATED PENILE LESIONS AMONG KENYAN 
MEN 
 
Abstract 
 
Background: HPV-associated penile lesions in men may increase the risk of 
HPV transmission to their female partners. Risk factor data on HPV-associated 
penile lesions are needed from regions with a high burden of cervical cancer. 
Methods: Visual inspection of the penis was conducted using a colposcope at 
the 24-month visit for a RCT of male circumcision in Kenya, from May 2006 to 
October 2007. All photos were read independently by two observers for quality 
control. 
Results: Of 267 men, 143 were circumcised and 124 uncircumcised. The 
median age was 22 years. Circumcised men had a lower prevalence of flat penile 
lesions (0.7%) versus uncircumcised (26.0%); age-adjusted OR=0.02; 95% CI: 
0.003-0.1. Men with flat lesions had increased odds of HPV DNA positivity (OR=5.5; 
95% CI: 2.2-13.3) and high HPV16/18/31 viral load (OR=7.6; 95% CI: 1.8-32.8) 
compared to men without flat lesions. Among men with flat penile lesions, HPV56 
(29.0%) and 16 (25.8%) were the most common types. 
Conclusions: Flat penile lesions are much more frequent in uncircumcised 
men, and associated with increased odds of HPV positivity and high viral load. This 
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study suggests circumcision reduces the prevalence of HPV-associated flat lesions 
and may ultimately reduce male to female HPV transmission. 
 
Introduction 
HPV infection is the central cause of cervical cancer in women and plays an 
important role in other anogenital cancers, including penile and anal cancers in men 
(1-4). Interventions that reduce HPV-associated penile lesions could be important to 
both men and women, since HPV-associated penile lesions in men may increase the 
risk of HPV transmission to their sexual partners (10). Risk factor data on HPV-
associated penile lesions are needed, especially from less-developed countries with 
a high burden of cervical cancer.  
Flat penile lesions are commonly found among male partners of women with 
CIN, but often go unnoticed without the application of acetic acid (51;53;56). Positive 
associations have been found between flat penile lesions, lack of condom use, HPV 
positivity and high HPV viral loads (51;57;58). More data however are needed to 
determine the type-specific distribution of HPV infection and whether other risk 
factors, including male circumcision, are associated with penile lesions. While 
circumcision has been previously associated with a lower point-prevalence of HPV 
infection (77-79) and a decreased incidence of high-risk HPV (43), it is unknown 
whether circumcision reduces the prevalence of flat penile lesions. Other types of 
common penile lesions, including papular lesions and pearly penile papules, have 
not been associated with HPV infection (51;52). It is unclear whether risk factors 
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other than HPV infection differ between flat penile lesions, papular lesions and 
pearly penile papules. 
The primary aim of this study was to determine the association between male 
circumcision status and HPV-associated flat penile lesions among high-risk men 
from Kisumu, Kenya. We also sought to investigate risk factors of ascertained penile 
lesions, including HPV viral load and type-specific HPV infection.   
 
Methods 
Study population and enrolment 
Uncircumcised men were screened between February 4, 2002 and 
September 6, 2005 in Kisumu, Kenya to participate in a RCT of male circumcision 
(6). The primary aim of the RCT was to determine the effectiveness of male 
circumcision in reducing HIV incidence. In brief, inclusion criteria included being 
uncircumcised, aged 18-24 years, HIV seronegative, sexually active, and having 
blood hemoglobin ≥90 g/L. Study participants were recruited from STI clinics, 
workplaces, and community organizations. For men assigned to the intervention 
group in the main RCT, circumcision was performed on the same day after HPV 
specimen collection or within a few days of the enrolment visit.  
Beginning May 5, 2006, RCT participants were invited to participate in a 
visual inspection examination of the penis with 3% acetic acid at the 24-month (final) 
follow-up visit. Of the 1,398 men enrolled in the RCT who had a 24-month visit date 
after May 5, 2006, 267 (19%) consented to participate in the VIA exam and were 
included in this sub-study. The study protocol was approved by the Institutional 
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Review Boards of the Universities of Illinois at Chicago, Manitoba, Nairobi, and 
North Carolina; RTI International; and the VU University Medical Center. 
 
Questionnaire, clinical examination, and specimen collection  
After undergoing informed consent, participants were administered a 
standardized questionnaire on sociodemographic characteristics and sexual 
behavior by a trained male interviewer at baseline and the 24-month visit. 
Participants also underwent a clinical examination by a trained physician or clinical 
officer at each visit (6).  Penile exfoliated cells were collected for HPV DNA detection 
at baseline prior to circumcision and at the 24-month visit from two anatomical sites: 
i. shaft and external foreskin tissue (shaft specimen) and ii. glans, coronal sulcus 
and inner foreskin tissue (glans specimen) using prewetted Type 3 Dacron swabs in 
separate conical tubes (18).   
Both penile cell samples were placed in individual 15-mL centrifuge tubes 
containing 2-mL of 0.01 mol/L Tris-HCl, 7.4 pH buffer, and processed on the day of 
collection at the UNIM clinic laboratory in Kisumu by centrifugation at high speed 
(maximum, 3000g) for 10 minutes. Excess Tris-HCl buffer was discarded using a 
Pasteur pipette, and the remaining cell pellet was resuspended in the same volume 
of 0.01 mol/L Tris-HCl buffer, and vortexed. Diluted cell pellets were then frozen at -
75°C. All samples were sent using a dry shipper to the Department of Pathology, VU 
University Medical Center, Amsterdam, the Netherlands, for HPV DNA testing. 
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Visual inspection exams 
Consenting study participants were screened at the 24-month visit by a 
physician or clinical officer for the presence of penile lesions by visual inspection 
aided by a colposcope for magnification. The first visual inspection exam was 
conducted before the application of 3% acetic acid. A second visual inspection exam 
was performed 2-3 minutes after the application of a 3% acetic acid solution with 
saturated gauze to the penile shaft, glans, coronal sulcus, frenulum, and the outer 
and inner foreskin tissue for uncircumcised men. The second exam was conducted 
to differentiate HPV-associated flat penile lesions, which are usually not visible 
without the application of 3% acetic acid. The lesion type and location were recorded 
on a standardized form corresponding to the two anatomical sites: i. the external 
penile shaft, including the outer foreskin in uncircumcised men, and from the base to 
the circumferential scar for circumcised men; and ii. the glans, coronal sulcus and 
frenulum, including the inner foreskin (retracted during this part of the exam) for 
uncircumcised men, and the part distal to the circumferential scar in circumcised 
men. Two digital photographs were taken of the ventral and dorsal side of the 
glans/coronal sulcus with the penile foreskin retracted for uncircumcised men both 
before and after acetic acid application. All photographs were also read in 
Amsterdam without knowing HPV data and in case of discrepancies (<10%) a 
consensus diagnosis was made to determine the final outcome. 
Penile lesions were categorized as follows: i. flat lesions (flat or slightly 
elevated, well demarcated, aceto-white lesions in which a capillary pattern can be 
seen); ii. condyloma acuminata (exophytic lesions with an irregular surface 
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commonly known as genital warts); iii. papular lesions (small exophytic papules 
usually located nearby the frenulum of the penis with a smooth surface on which a 
hyperkeratinized layer could be present) (51); and iv. pearly penile papules (small 
exophytic papules located around the corona of the glans penis and presenting in 1 
to 4 rows) (52).   
 
HPV DNA, HPV viral load and STI testing 
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system 
(Hamilton, Germany) according to manufacturers’ instructions. Presence of human 
DNA was evaluated by beta-globin specific PCR, followed by agarose gel 
electrophoresis. HPV positivity was assessed by GP5+/6+ PCR followed by 
hybridization of PCR products using an EIA readout with two HPV oligoprobe 
cocktail probes that, together, detect 44 HPV types HPV6, 11, 16, 18, 26, 30, 31, 32, 
33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64, 66, 67, 
68, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 
and MM4subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), cand85, 86, 
cand89 (equivalent to CP6108) and JC9710. Subsequent HPV genotyping was 
performed by RLB hybridization of PCR products, as described previously in 
Chapter 3 (64;65). HPV16, 18 and 31 viral loads were subsequently determined 
using a real time PCR assay and a LightCycler instrument (Roche) as previously 
described in Chapter 3 (69). High HPV DNA viral load was defined as positive when 
HPV16, 18 or 31 specimen viral loads were >250 copies per scrape in either the 
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glans or shaft specimens (56). All other specimens containing HPV 16, 18 or 31 
DNA were considered to have low HPV16/18/31 viral load.   
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered 
high-risk types. HPV types detected by EIA but not by RLB genotyping were 
designated as HPVX, indicating a type, sub-type or variant not detectable with 
probes used for RLB hybridization. HPV infections with multiple HPV types were 
considered high-risk if one or more high-risk HPV types were detected. Low-risk 
types included all other known HPV types. Men with untyped HPV infections (i.e. 
HPVX) were excluded from analyses involving high-risk and low-risk HPV 
categorizations unless they also had a known high-risk HPV type detected.     
Urine samples were tested for N. gonorrhea and C. trachomatis infections by 
PCR-based methods (Roche Diagnostics).  Serum specimens were tested for HSV-
2 antibody (Kalon) and for HIV antibody using two rapid tests (Determine, Abbott 
Diagnostic Division, Hoofddorp, Netherlands; and Unigold, Trinity Biotech, Wicklow, 
Ireland) and confirmed by double ELISA (Adaltis Inc, Montreal, Canada; Trinity 
Biotech, Wicklow, Ireland) at the University of Nairobi.   
 
Statistical methods 
Pearson’s χ2 and Fisher’s exact tests were used to assess differences in: i. 
baseline risk factors between men participating in the VIA exam and all other men 
enrolled in the parent RCT; ii. 24-month risk factors between circumcised and 
uncircumcised men; and iii. flat penile lesion prevalence stratified by circumcision 
status. Prevalence ORs and corresponding 95% CIs for potential risk factors of flat 
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penile lesions were estimated via age-adjusted, univariate logistic regression 
models. A multivariate logistic regression model was used to estimate the OR for flat 
penile lesions and HPV DNA positivity adjusted for age and male circumcision status 
since these variables were believed a priori to be potential confounders. Analyses 
were repeated for papular lesions and pearly penile papule outcomes.  
Of 151 circumcised men who consented to VIA exams, 8 (5.3%) were 
originally assigned to the control arm of the trial but were circumcised before their 
24-month visit and therefore excluded from analyses. Results were similar with the 
inclusion of these 8 men. Beta-globin positivity was 87.2% in the glans specimens 
and 73.6% in the shaft specimens. Reported analyses utilized HPV DNA data from 
all penile exfoliated cell specimens regardless of beta-globin positivity. Results did 
not differ substantially when analyses were restricted to beta-globin positive 
samples.  
 
Results 
At baseline, men who participated in the VIA exam (N=267) were more likely 
to have ≥2 sex partners during the past 12 months (p<0.001), live with their female 
sexual partner (p=0.01) and be randomized to the intervention arm (p=0.06), as 
compared to all other RCT participants (N=2,517) (Table 5.1). All other baseline risk 
factors assessed were similar between men who did and did not participate in the 
VIA study. 
At the 24-month visit, of the 267 men consenting to undergo the penile lesion 
examination, 143 (53.6%) were circumcised and 124 (46.4%) were uncircumcised. 
 63 
The median age was 22 years (range 20-26).  One participant was HIV seropositive 
(0.37%), while 27 were seropositive for HSV-2 (14.6%) at the 24-month visit.  Less 
than 2% of men had laboratory diagnosed N. gonorrhea or C. trachomatis infections, 
or reported having an STI within the last 6 months. The median number of female 
sexual partners in the previous 12 months was 2 women (range 0-14). No men 
reported having a male sexual partner in their lifetime. The vast majority of men 
(99%) reported bathing daily. Risk factors assessed at the 24-month visit did not 
differ between circumcised and uncircumcised men except circumcised men were 
more likely to be HPV negative (p=0.01), and have two or more female sexual 
partners in the previous 12 months (p=0.04) (Table 5.2).    
 
Prevalence of penile lesions 
A total of 33 (12.4%) men had flat penile lesions detected after application of 
3% acetic acid. The foreskin (or foreskin remnant among circumcised men) was the 
most common site where flat lesions were detected (10.2%), followed by the 
frenulum (3.4%) and then the glans (2.6%) (Table 5.3). The prevalence of flat 
lesions was higher among uncircumcised men (26.0%) than circumcised men 
(0.7%), respectively (p<0.001), with only one circumcised participant having a flat 
lesion, which was on the foreskin remnant. Compared to circumcised men, men who 
were uncircumcised were more likely to have flat lesions detected at the foreskin 
(p<0.001), frenulum (p<0.001) and glans (p=0.004). No flat lesions were detected on 
the penile shaft of any participant. Two uncircumcised participants were diagnosed 
with condyloma acuminata. Papular lesions (n=129; 48.3%) and pearly penile 
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papules were common (n=183; 68.5%). Uncircumcised men had a lower prevalence 
of papular lesions (34.7% vs. 60.1% in circumcised; p<0.001) and pearly penile 
papules (61.3% vs. 74.8%; p=0.02). 
 
Risk factors of flat penile lesions 
After age adjustment, circumcised men were less likely to have flat penile 
lesions versus uncircumcised men (0.7% vs. 26.0%; OR=0.02; 95% CI: 0.003-0.1) 
(Table 5.4). Flat penile lesions were more common among men with who were HPV 
DNA positive at the glans or shaft (21.6% vs. 4.8% in HPV-negative men; OR=5.5; 
95% CI: 2.2-13.3). A strong association was also found between flat penile lesions 
and high-risk HPV DNA (OR=8.0; 95% CI: 3.2-19.9 vs. HPV-negative) and HPV 
DNA detected at the glans only (OR=6.3; 95% CI: 2.7-15.0) (Table 5.4). In a 
multivariate model, high-risk HPV DNA remained a strong risk factor of flat penile 
lesions even after controlling for age and male circumcision status (OR=8.3; 95% CI: 
3.0-22.8 vs. HPV-negative). 
Compared to men who were HPV DNA negative, participants with high 
HPV16, 18 or 31 viral loads were much more likely to have flat penile lesions 
(OR=7.6; 95% CI: 1.8-32.8). Even men with low viral loads were more likely to have 
flat penile lesions compared to HPV-negative men (OR=4.3, 95% CI: 1.1-16.6). 
Compared to men who were HPV DNA negative, a particularly strong association 
was found between high HPV16/18/31 viral load in the glans and the presence of flat 
penile lesions (OR=12.3; 95% CI: 2.6-58.8) with a weaker association found in the 
shaft (OR=5.1; 95% CI: 0.8-31.4). A higher reported number of female sexual 
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partners in the last 12 months was associated with reduced odds of flat penile 
lesions (OR=0.5; 95% CI: 0.2-1.0 for 0-1 vs. ≥2 partners) (Table 5.4), although this 
association was no longer significant after adjusting for age and circumcision status 
(OR=0.5, 95% CI: 0.2-1.2). Other risk factors assessed including education, income, 
condom use in the last 6 months and years of sexual activity were not significantly 
associated with prevalence of flat penile lesions (Table 5.4). 
  
Risk factors of papular lesions and pearly penile papules 
Circumcised men were more likely to have papular lesions (OR=2.9; 95% CI: 
1.7-4.7 vs. uncircumcised) in the age-adjusted model (Table 5.4). High-risk HPV was 
not significantly associated with papular lesions (OR=0.6, 95% CI: 0.3-1.1 vs. HPV-
negative) after controlling for age and circumcision status. Male circumcision and 
younger age (22-23 vs. ≥24 years) were associated with pearly penile papules in 
age-adjusted models (ORs=1.9; 95% CI: 1.1-3.2 and 2.2; 95% CI: 1.2-4.2) (Table 
5.4).  
 
HPV type distribution among men with and without flat penile lesions 
Among men with flat penile lesions, 30 individual HPV types were detected, 
with high-risk HPV 56 (29.0%) and 16 (25.8%) the most common HPV types within 
single or multiple HPV infections. The next three most common HPV types were 
high-risk HPV52 (19.4%), 35 (12.9%) and 66 (12.9%).  All other HPV types detected 
(n=25) had an HPV prevalence of less than 10%: 18, 31, 33, 45, 51, 58, 59, 68, 6, 
26, 30, 34, 40, 42, 43, 55, 61, 67, 72, 73, 81, 82 83, 89 and JC9710.   
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A total of 41 HPV types were detected among men without flat penile lesions, 
with HPV16 the most common type (9.3%) within single or multiple infections. The 
next four most common known HPV types were HPV45 (4.0%), HPV51 (3.6%), 
HPV58 (3.6%) and HPV66 (3.6%). HPVX infections were found in 4.4% of men 
without penile lesions. All other HPV types detected (n=35) were found in ≤3.1% of 
participants, and included HPV18, 31, 33, 35, 39, 52, 56, 59, 68, 6, 11, 26, 32, 40, 
42, 43, 44, 53, 54, 55, 61, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 85, 86, 89 and 
JC9710.  
The prevalences of the 5 most common individual HPV types among men 
with flat penile lesions were higher than the corresponding HPV prevalences among 
men without flat penile lesions (Figure 5.1).  Multiple HPV types (defined as having ≥ 
2 different individual HPV types) were less common among men without flat penile 
lesions compared to men with flat penile lesions detected (19.6% vs. 67.7%, 
respectively; p<0.001).  
 
Discussion 
Male circumcision was strongly associated with reduced odds of flat penile 
lesions. Men with flat penile lesions had a higher prevalence of HPV infection, than 
men without flat lesions. High-risk HPV infection and high HPV16/18/31 viral load in 
the glans were particularly strong risk factors of flat penile lesions.  
The prevalence of flat penile lesions among uncircumcised men in our study 
population (26%) was higher than that found among uncircumcised participants in a 
previous study (17%) of men in the Netherlands who self-reported no known STI 
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infections (56). The prevalence of flat lesions among circumcised men in both 
studies was <1%. The higher flat lesion prevalence among uncircumcised men in 
our study could also potentially be due to the younger age of our study population.  
Our results are also consistent with previous studies that found an association 
between flat penile lesions and HPV using PCR or in situ hybridization methods 
(51;54). HPV prevalence among men with flat penile lesions in our study population 
(77%) was similar to that observed among 175 male sexual partners of women with 
CIN from the Netherlands (72%) (51). Flat penile lesions were strongly associated 
with high-risk HPV infection and high HPV16/18/31 viral load especially in the glans, 
supporting findings from previous studies that HPV might play an important role in 
the etiology of these lesions (51;54;55;80). Flat penile lesions could also be a useful 
parameter for evaluating efficacy of prophylactic HPV16/18 vaccines, due to their 
common occurrence and strong associations with high-risk HPV and HPV16/18/31 
viral load. 
Circumcision was associated with increased odds of papular lesions and 
pearly penile papules. Papular lesions and pearly penile papules are likely not 
sexually transmitted and have not been found to be associated with HPV infection in 
previous reports (51;52;59). The association found between circumcision and 
papular lesions and pearly penile papules might be due to small mechanical traumas 
during intercourse or a tissue reaction following the circumcision procedure (81).  
To our knowledge, this is the first study to investigate multiple risk factors, 
including HPV, for penile lesions among men from sub-Saharan Africa, where the 
burden of ICC is among the highest worldwide.  Study advantages also include the 
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use of a sensitive PCR assay to detect a broad range of individual HPV types and 
the collection of data on numerous potential risk factors. Additionally, all photos 
taken of penile lesions were double read in Amsterdam without knowledge of HPV 
status for quality control to reduce misclassification of penile lesions.  
A study limitation is that penile lesions were diagnosed by colposcopy.  
Taking biopsies of the ascertained lesions was considered too invasive for this study 
population, which was participating in a RCT. Therefore, HPV infection could not be 
detected directly from biopsy specimens and histological diagnosis of penile lesions 
was not possible. Previous reports of flat penile lesions indicate that these lesions 
usually represent hyperplasia or low grade penile intraepithelial neoplasia, although 
a minority of lesions may be high grade (10;51). Only three of the large number of 
HPV types were assessed for HPV DNA viral load in this study. Men categorized as 
having low HPV16/18/31 viral load may have had a high viral load for an HPV type 
that was not assessed. Our sample was too small to restrict the analysis to men with 
single HPV type infections. Thus, viral load analyses should be interpreted with 
caution. 
Compared to all other RCT participants, men who participated in this study 
were similar in respect to their baseline risk factors except that VIA participants were 
more likely to have two or more sexual partners in the previous 12 months, live with 
their female partner and be randomized to the intervention arm of the trial. While 
selection bias appeared to be minimal, our findings should be interpreted with 
caution as this was a relatively small subset of men from the RCT. The prevalence 
of STIs other than HPV infection was also low in our study population, and hence 
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important associations between penile lesions and other STIs might have been 
missed. Future studies are needed to determine if there are associations between 
laboratory-diagnosed STIs and penile lesions. 
Male circumcision was strongly associated with reduced odds of flat penile 
lesions. Because flat penile lesions were also strongly associated with high-risk HPV 
infection and high HPV16/18/31 viral load, circumcision may also reduce male to 
female high-risk HPV transmission. Additionally, since prophylactic HPV vaccines 
may not be readily available to men in many less developed countries and current 
HPV vaccines do not include all high-risk HPV types, circumcision may provide a 
useful intervention to prevent HPV-associated penile lesions and ultimately invasive 
cervical cancer in developing countries.  
  
 70 
Table 5.1 Comparison of baseline characteristics for men enrolled in the randomized 
controlled trial of male circumcision who did and did not participate in the visual inspection 
with acetic acid sub-study 
 
  
Participated in 
VIA sub-study 
(n=267)  
Did not participate in 
VIA sub-study 
(n=2517) 
  
Risk Factor   n (%)*   n (%)*  p-value† 
       
Age (years)      0.24 
≥22  69 (25.8)  776 (30.8)   
20-21  112 (42.0)  973 (38.7)   
≤19  86 (32.2)  768 (30.5)   
Randomization Assignment      0.06 
    Uncircumcised  119 (44.6)  1274 (50.6)   
    Circumcised  148 (55.4)  1243 (49.4)   
HPV DNA positivity‡       
    HR-positive  95 (39.4)  685 (36.3)  0.62 
LR-positive  26 (10.8)  220 (11.6)   
Negative  120 (49.8)  984 (52.1)   
Education      0.33 
Secondary or tertiary  169 (63.3)  1668 (66.3)   
Primary or none  98 (36.7)  849 (33.7)   
Employment status      0.68 
No Income  92 (34.5)  899 (35.7)   
Income   175 (65.5)  1618 (64.3)   
Condom use last 6 months       
>50%  85 (34.7)  787 (36.5)  0.85 
≤50%  95 (38.8)  806 (37.4)   
Never  65 (26.5)  561 (26.0)   
Marital Status       
Not living with partner  243 (91.0)  2374 (94.7)  0.01 
Living with partner  24 (9.0)  132 (5.3)   
Age at first intercourse 
(years)     
  
    16-21  129 (50.0)  1239 (51.4)  0.66 
    8-15  129 (50.0)  1170 (48.6)   
Partners in last 12 months       
    0-1  71 (26.8)  1012 (40.6)  <0.001 
    ≥2  194 (73.2)  1481 (59.4)   
Lifetime # of female partners       
    1-4  117 (48.3)  1282 (54.5)  0.18 
    5-7  61 (25.2)  535  (22.8)   
    ≥8  64 (26.5)  534 (22.7)   
Years of sexual activity       
    0-3  77 (30.0)  789 (29.0)  0.46 
    4-5  74 (28.8)  587 (24.3)   
    6-7  58 (22.6)  566 (23.4)   
    8-14  48 (18.7)  473 (19.6)   
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Table 5.1 continued       
  
Participated in 
VIA sub-study 
(n=267)  
Did not participate in 
VIA sub-study 
(n=2517) 
  
Risk Factor   n (%)*   n (%)*  p-value† 
HSV-2-seropositive        
    No  182 (71.4)  1748 (72.3)  0.76 
    Yes  73 (28.6)  670 (27.3)   
N. gonorrhea       
Positive   6 (2.3)  48 (1.9)  0.64** 
Negative  254 (97.7)  2436 (98.1)   
C. trachomatis       
Positive  16 (6.2)  108 (4.4)  0.21** 
Negative  244 (93.8)  2375 (95.6)   
Self-reported STI††       
No  248 (97.2)  2015 (98.1)  0.49** 
Yes   7 (2.8)   42 (2.0)   
       
VIA: visual inspection with acetic acid; HPV: human papillomavirus; HR: high-risk; LR: low-risk; 
HSV-2: herpes simplex virus type 2; STI: sexually transmitted infection 
*Percentages do not include missing values 
†
P-value comparing men who did and did not participate in the VIA sub-study using Pearson’s chi-
square test unless otherwise noted.  
‡
Men with HPVX infections were excluded from high and low-risk HPV categorizations unless a 
high-risk HPV type was detected.     
**Fisher’s exact test       
††
Sexually transmitted infection (current or within the last 6 months) 
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Table 5.2 Comparison of risk factors assessed at the 24-month follow-up visit between 
circumcised versus uncircumcised men participating in the visual inspection with acetic acid 
sub-study 
 
Circumcised 
(n=143) 
Uncircumcised 
(n=124) 
 
 
Risk Factor   N   n %*   N %*   P-value† 
 
Age (years)  
≥24 70 37 25.9 33 26.6 0.96 
22-23 115 61 42.7 54 43.6  
≤21 82 45 31.5 37 29.8  
HPV DNA positivity‡  
    HR-positive 77 30 22.7 47 39.8 0.01 
LR-positive 28 17 12.9 11 9.3  
Negative 145 85 64.4 60 50.9  
Education**  
Secondary or tertiary 169 87 60.8 82 66.1 0.37 
Primary or none 98 56 39.2 42 33.9  
Employment status**  
No Income 175 97 67.8 78 62.9 0.40 
Income  92 46 32.2 46 37.1  
Condom use last 6 months  
>50% 108 53 41.7 55 53.4 0.07 
≤50% 66 44 34.6 22 21.4  
Never 56 30 23.6 26 25.2  
Marital Status  
Not living with partner 197 100 69.9 97 78.2 0.12 
Living with partner 70 43 30.1 27 21.8  
Age at first intercourse 
(years) 
 
    16-21 91 47 35.6 44 36.4 0.90 
    8-15 162 85 63.6 77 63.6  
Partners in last 12 months  
    0-1 121 56 39.7 65 52.4 0.04 
    ≥2 144 85 60.2 59 47.6  
HSV-2-seropositive   
No 158 89 86.4 69 84.2 0.67 
Yes 27 14 13.6 13 15.8  
Lifetime # of female 
partners 
 
    1-4 87 45 37.2 42 37.2 0.42 
    5-7 62 36 29.7 26 23.0  
    ≥8 85 40 33.1 45 39.8  
HPV: human papillomavirus; HR: high-risk; LR: low-risk; HSV-2: herpes simplex virus type 2 
*Percentages do not include missing values 
† 
P-value comparing circumcised versus uncircumcised men using Pearson’s chi-square test 
‡
Men with HPVX infections were excluded from high and low-risk HPV categorizations unless a high-
risk HPV type was detected.    
 
**Assessed at the baseline visit 
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Table 5.3 Prevalence of flat penile lesions after 3% acetic acid application by penile site 
among circumcised and uncircumcised men from Kisumu, Kenya 
 
  
Overall  
(N=267)  
Circumcised 
(N=143)  
Uncircumcised 
(N=124) 
 P-value† 
  n %*  n %*  n %*   
            
All sites combined  33 12.4  1 0.7  32 26.0  <0.001 
 Foreskin‡  27 10.2  1 0.7  26 21.0  <0.001 
 Frenulum  9 3.4  0 0.0  9 7.3  <0.001 
 Glans  7 2.6  0 0.0  7 5.7  0.004 
 Missing    1      1    
*Percentage of men does not include missing values     
†
Comparing circumcised and uncircumcised men using Fisher’s exact test 
‡
Foreskin remnant among circumcised men
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Table 5.4 Age-adjusted prevalence odds ratios for risk factors of penile lesions among 267 Kenyan men at the 24-month visit 
 
         
    Flat penile lesions*  Papular Lesions  Pearly Penile Papules  
    n=33; HPV%=77.4%  n=129; HPV%=39.2%  n=183; HPV% = 41.1% 
            
Risk Factor   N   n OR (95% CI) †   n OR (95% CI) †   n OR (95% CI) † 
            
Age (years)            
≥24  70  9 1.0 (Reference)  31 1.0 (Reference)  41 1.0 (Reference) 
22-23  115  10 0.7 (0.3, 1.7)  59 1.3 (0.7, 2.4)  87 2.2 (1.2, 4.2) 
≤21  82  14 1.4 (0.6, 3.5)  39 1.1 (0.6, 2.2)  55 1.4 (0.7, 2.8) 
Circumcision status            
    Uncircumcised  124  32 1.0 (Reference)  43 1.0 (Reference)  76 1.0 (Reference) 
    Circumcised  143  1 0.02 (0.003, 0.1)  86 2.9 (1.7, 4.7)  107 1.9 (1.1, 3.2) 
HPV DNA positivity‡            
    Negative  145  7 1.0 (Reference)  76 1.0 (Reference)  103 1.0 (Reference) 
Positive  112  24 5.5 (2.2, 13.3)  49 0.7 (0.4, 1.2)  72 0.7 (0.4, 1.3) 
    LR-positive  28  2 1.6 (0.3, 8.0)  17 1.4 (0.3, 3.2)  18 0.7 (0.3, 1.7) 
    HR-positive  77  22 8.0 (3.2, 19.9)  27 0.5 (0.3, 0.9)  48 0.7 (0.4, 1.3) 
HPV DNA positivity in glans‡            
    Negative  163  8 1.0 (Reference)  87 1.0 (Reference)  119 1.0 (Reference) 
    Positive  95  23 6.3 (2.7, 15.0)  39 0.6 (0.4, 1.0)  56 0.5 (0.3, 0.9) 
       LR-positive  29  3 2.3 (0.6, 9.3)  18 1.4 (0.6, 3.2)  18 0.6 (0.3, 1.3) 
       HR-positive  64  20 8.9 (3.6, 21.7)  20 0.4 (0.2, 0.8)  36 0.5 (0.3, 0.9) 
HPV DNA positivity in shaft‡            
    Negative  188  16 1.0 (Reference)  94 1.0 (Reference)  128 1.0 (Reference) 
    Positive  69  15 2.9 (1.3, 6.3)  31 0.8 (0.5, 1.5)  47 1.1 (0.6, 1.9) 
       LR-positive  25  6 3.3 (1.1, 9.6)  11 0.8 (0.3, 1.8)  15 0.7 (0.3, 1.6) 
       HR-positive  39  9 3.2 (1.3, 7.9)  16 0.7 (0.4, 1.5)  28 1.4 (0.6, 3.0) 
HPV 16/18/31 viral load**            
HPV negative  145  7 1.0 (Reference)  76 1.0 (Reference)  103 1.0 (Reference) 
Low    22  4 4.3 (1.1, 16.6)  9 0.6 (0.3, 1.6)  14 2.0 (0.9, 4.3) 
High  14  4 7.6(1.8, 32.8)  4 0.4 (0.1, 1.3)  8 1.3 (0.8, 2.2) 
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Table 5.4 continued            
    Flat penile lesions*  Papular Lesions  Pearly Penile Papules  
    n=33; HPV%=77.4%  n=129; HPV%=39.2%  n=183; HPV% = 41.1% 
            
Risk Factor   N   n OR (95% CI) †   n OR (95% CI) †   n OR (95% CI) † 
            
Education††            
Secondary or tertiary  169  17 1.0 (Reference)  80 1.0 (Reference)  113 1.0 (Reference) 
Primary or none  98  16 1.6 (0.8, 3.5)  49 1.1 (0.7, 1.8)  70 1.2 (0.7, 2.1) 
Employment status††            
No Income  175  20 1.0 (Reference)  85 1.0 (Reference)  122 1.0 (Reference) 
Income   92  13 1.4 (0.7, 3.2)  44 1.0 (0.6, 1.6)  61 0.9 (0.5, 1.5) 
Condom use last 6 months            
>50%  108  13 1.0 (Reference)  50 1.0 (Reference)  77 1.0 (Reference) 
≤50%  66  4 0.5 (0.1, 1.5)  32 1.1 (0.6, 2.0)  46 1.1 (0.5, 2.1) 
Never  56  11 1.7 (0.7, 4.2)  26 1.0 (0.5, 2.0)  35 0.8 (0.4, 1.6) 
Marital Status            
Not living with partner  197  26 1.0 (Reference)  99 1.0 (Reference)  141 1.0 (Reference) 
Living with partner  70  7 0.8 (0.3, 1.9)  30 0.7 (0.4, 1.3)  42 0.6 (0.3, 1.1) 
Age at first intercourse (years)            
    16-21  91  11 1.0 (Reference)  48 1.0 (Reference)  62 1.0 (Reference) 
    8-15  162  22 1.1 (0.5, 2.4)  76 0.8 (0.5, 1.3)  111 1.0 (0.6, 1.8) 
Partners in last 12 months            
    0-1  121  20 1.0 (Reference)  60 1.0 (Reference)  79 1.0 (Reference) 
    ≥2  144  13 0.5 (0.2, 1.0)  68 0.9 (0.6, 1.5)  103 1.4 (0.8, 2.3) 
HSV-2-seropositive             
No  158  21 1.0 (Reference)  82 1.0 (Reference)  111 1.0 (Reference) 
Yes  27  2 0.5 (0.1, 2.3)  12 0.7 (0.3, 1.6)  19 0.9 (0.4, 2.3) 
Lifetime # of female partners            
    1-4  87  14 1.0 (Reference)  37 1.0 (Reference)  54 1.0 (Reference) 
    5-7  62  4 0.4 (0.1, 1.1)  36 1.9 (1.0, 3.6)  44 1.5 (0.7, 3.1) 
    ≥8  85  14 1.0 (0.4, 2.2)  38 1.2 (0.6, 2.1)  60 1.7 (0.9, 3.2) 
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Table 5.4 continued            
    Flat penile lesions*  Papular Lesions  Pearly Penile Papules  
    n=33; HPV%=77.4%  n=129; HPV%=39.2%  n=183; HPV% = 41.1% 
            
Risk Factor   N   n OR (95% CI) †   n OR (95% CI) †   n OR (95% CI) † 
            
Years of sexual activity            
    0-3  63  7 1.0 (Reference)  33 1.0 (Reference)  46 1.0 (Reference) 
    4-5  64  12 1.9 (0.7, 5.2)  28 0.7 (0.4, 1.5)  41 0.7 (0.3, 1.5) 
    6-7  73  7 0.9 (0.3, 2.9)  31 0.7 (0.4, 1.4)  52 1.0 (0.4, 2.0) 
    8-14  52  7 1.3 (0.4, 4.6)  31 1.7 (0.7, 3.8)  33 0.8 (0.4, 2.1) 
            
OR: Odds ratio; CI: confidence interval; HPV: human papillomavirus; HR: high-risk; LR: low-risk; HSV-2: herpes simplex virus type 2 
*Visible after the application of 3% acetic acid     
†
Odds ratios adjusted for age categorized as ≥24, 22-23 and ≤21 years  
‡
Men with HPVX infections were excluded from high and low-risk HPV categorizations unless a high-risk HPV type was detected.    
 
**High HPV viral load defined as HPV 16, 18 and/or 31 >250 copies/scrape in the glans or shaft HPV specimens. All other specimens containing 
HPV 16, 18 or 31 were considered to have low HPV16/18/31 viral load.   
††
Assessed at the baseline visit      
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  Figure 5.1: Human papillomavirus (HPV) prevalence and 95% confidence intervals for the five most common  
  HPV types among men with flat penile lesions compared to men without flat penile lesions. 
 
  
 
 
 
 
CHAPTER 6. 
CONCLUSIONS 
 
 
Summary of Findings and Public Health Significance  
The first aim of this dissertation was to investigate the natural history of HPV 
infection in a cohort of uncircumcised Kenyan men aged 17-24. The IR for the first 
HPV type detected was 24.3/1,000 person-months. As hypothesized, this was within 
the range of previously reported IR estimates (18-35/1,000 person-months) 
(36;37;39). The natural history of HPV infection among men may be different than 
that previously described for women, as men appear to have a higher incidence of 
HPV infection compared to women. Unlike women, who generally show lower rates 
of clearance for high versus low-risk HPV types, men in our study showed a similar 
pattern of high and low-risk types. 
HPV16 was the most prevalent HPV type (9.2%) in this population and also 
had the highest incidence with a rate of 5.5/1,000 person-months. The high rate of 
acquisition of HPV16 has a clear implication for cancer risk among men and their 
sexual partners as HPV16 is the most common HPV type found in penile cancer 
among men (2), cervical, vulvar and vaginal cancers among women (1;19) and anal 
and oropharyngeal cancers among both sexes (3;4). IRs for penile cancer in less 
developed countries including those in Latin America and sub-Saharan Africa are 
among the highest worldwide (82).  
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The second aim of this dissertation was to determine the association between 
penile lesions and HPV DNA positivity, HPV viral load and socio-demographic risk 
factors of ascertained HPV-associated penile lesions. As hypothesized, lack of male 
circumcision and high HPV16/18/31 viral load were strongly associated with 
increased odds of HPV-associated flat penile lesions. A higher number of sexual 
partners in the previous 12 months was also associated with higher odds of flat 
penile lesions in age-adjusted univariate analyses but was not significant after 
controlling for age, circumcision and HPV infection. Although condom use was 
associated with flat penile lesion regression in a previous study (57), condom use 
was not associated with the prevalence of flat penile lesions in this study.  
Flat penile lesions could be a useful parameter for evaluating efficacy of 
prophylactic HPV16/18 vaccines, given their strong association with high-risk HPV 
and HPV16/18/31 viral load. Additionally, because prophylactic HPV vaccines may 
not be readily available to men in developing countries and current HPV vaccines do 
not include all high-risk HPV types, circumcision may provide a useful intervention to 
prevent against HPV-associated penile lesions and ultimately ICC in developing 
countries. Male circumcision was associated with higher odds of papular lesions and 
pearly penile papules, which might be due to a tissue reaction after the circumcision 
procedure (81).   
Three RCTs of male circumcision and HIV acquisition have been conducted 
in sub-Saharan Africa to date with results indicating that male circumcision reduces 
the risk of HIV acquisition by approximately 60% (6;83;84). Male circumcision has 
also been found to significantly reduce the acquisition of HSV-2 infection and the 
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prevalence, acquisition and clearance of HPV infection (43;77). Because male 
circumcision has been found to have a strong reduction in the acquisition of HIV and 
other STIs, its reduced association with HPV-associated penile lesion prevalence 
further emphasizes the utility of male circumcision as an intervention for HIV/STI 
prevention in developing countries.   
A systematic review of the acceptability of male circumcision in sub-Saharan 
Africa among men aged 13-80 years by Westercamp and Bailey in 2006 indicated 
that more than half of uncircumcised men in most studies would be willing to 
become circumcised if it was safe and effective against HIV incidence (85). 
Circumcising men around puberty or as infants were the preferred ages for 
circumcision. There are many remaining challenges regarding the implementation of 
male circumcision in developing countries however, including the need for extensive 
training and resources to ensure safety (86). Because male circumcision is not 
100% effective against HIV/STI acquisition and HPV-associated flat lesions, 
comprehensive intervention programs are also needed to prevent men from 
increasing their sexual risk behaviors after circumcision (87).   
 
Strengths and Limitations 
Strengths 
The findings in this dissertation are the first to characterize the natural history 
of low-risk HPV infections among men from sub-Saharan Africa.  Few prospective 
studies have described the natural history of HPV infection among men (Table 2.1), 
and to my knowledge, this is the largest study among men to date. A sensitive 
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GP5+/6+ PCR assay was used to detect a wide range of HPV types in a central 
laboratory allowing the comparisons of natural history studies among women. 
Separate HPV testing for glans and shaft specimens also allowed for stratified 
analyses by anatomical site.   
The results of the second aim of this dissertation, to my knowledge, are the 
first to investigate the association between circumcision and HPV-associated flat 
penile lesions, and the only study to investigate risk factors of HPV-associated 
penile lesions among men from Africa. Study advantages also included the inclusion 
of data on numerous potential risk factors, a sensitive PCR assay to detect a broad 
range of HPV types and a real-time PCR assay to detect viral loads from three high-
risk HPV types. Penile lesions are often diverse in their presentation, which can 
influence the accuracy of peniscopy (51). All photos taken of penile lesions were 
double read in Amsterdam for quality control in order to prevent the misclassification 
of penile lesions.  
 
Limitations 
The 12-month interval between each visit was a limitation of the natural 
history analyses. Participants could have acquired a new HPV infection and cleared 
it before the subsequent follow-up visit. Incident HPV infections could have also 
occurred and persisted until they had the opportunity to be detected at the 12 or 24-
month follow-up visits. Thus, IRs for the first HPV type detected likely underestimate 
the actual IR of HPV infection. We were also unable to determine if a participant had 
a persistent HPV infection, or cleared and re-acquired another HPV infection of the 
 82 
same type within the 12-month interval. This may have led to an overestimation of 
HPV persistence over a 12-month period in our study as a participant who cleared 
an infection and re-acquired an HPV infection with the same HPV type during the 12 
month period also met the definition for having a persistent infection detected.  A 
reliable median duration of clearance could also not be estimated due to the length 
of the interval between study visits, as the median time to clearance in two previous 
studies was 3-6 months.  
There was a potential lack of complete ascertainment of penile HPV infection 
since this study used HPV DNA results from sampling two anatomical sites (the 
shaft and the glans/coronal sulcus). A validation study among a subset of men from 
this study population indicated that sampling from the urethra did not increase the 
sensitivity of HPV detection, but samples from the scrotum were not included in this 
study (34). Sampling from the scrotum however, has not been shown to substantially 
increase the sensitivity in HPV detection over that found in the shaft and 
glans/coronal sulcus, especially among uncircumcised men (33). Sampling variability 
in penile exfoliated cell collection was another potential limitation in this study. All 
clinical officers were trained and followed a standard protocol for HPV sample 
collection in order to reduce any sampling variability both between and within 
subjects.    
A limitation of all natural history studies of HPV infection among men, 
including this study, is the lack of complete ascertainment of HPV-associated penile 
lesions. Because flat penile lesions are associated with higher HPV viral loads, 
screening for these lesions in natural history studies among men could help 
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differentiate a positive HPV result with a productive HPV infection from one with a 
low HPV copy number or HPV contamination from a sexual partner (10). However, 
HPV-associated flat lesions are difficult to detect since they are not visible without 
the application of acetic acid and given the low percentage of participation in this 
study, implementing VIA exams in order to screen for these lesions can also be 
difficult.  
The loss to follow-up and non-adherence to circumcision assignment were 
also potential limitations of the natural history analyses. Compared to all other men 
with a baseline HPV result (n=780), men missing 12 or 24-month HPV results or 
circumcised before their 24-month visit (n=322) were similar in respect to their 
baseline characteristics except that they had a slightly lower prevalence of C. 
trachomatis infection (1.9 vs. 4.8%, respectively; p=0.03). 
Beta-globin positivity was relatively low in this study population, especially in 
the shaft specimens. Beta-globin may not be the optimal control for HPV DNA 
testing in men as penile exfoliated cells, especially those from the shaft, are more 
keratinized and may contain less human DNA compared to cervical cells (18). 
Results in this dissertation did not differ substantially when analyses were restricted 
to beta-globin positive samples, which is consistent with the idea that HPV copies 
amplified by PCR techniques can often be higher than those of the beta-globin gene 
(18). 
  The generalizability of our results may be limited given that participants in 
this study were a subset of men from one region in Kenya who met criteria to 
participate in a RCT that entailed circumcision (e.g. aged 18-24, uncircumcised and 
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HIV seronegative at enrolment). Compared to circumcised men, uncircumcised men 
may be more likely to acquire (43) and less likely to clear HPV infections (42;43), 
thus the findings from the first aim of this dissertation should be compared to those 
of circumcised populations with caution. Additionally, the relatively small age range 
of included participants limited the assessment of HPV clearance by age.  
There was also a low participation rate (19%) for the VIA exam. Men in the 
VIA exam were more likely to have ≥2 sexual partners in the past 12 months 
compared to all other men enrolled in the RCT. However, men in the VIA sub-study 
did not have a higher baseline prevalence of HPV or other STIs and the number of 
sexual partners between the 12 and 24-month visits was not associated with penile 
lesions in this study after controlling for age and circumcision status. Although 
selection bias appeared to be minimal, our findings should be interpreted with 
caution as this was a relatively small subset of men from the main RCT. The small 
sample size of men who participated in the VIA exam (n=267) also limited the 
number of ascertained penile lesions. For example, since there were only two cases 
of condyloma acuminata detected, a risk factor analysis for this type of lesion could 
not be conducted.  
Penile lesions were diagnosed by colposcopy, as taking biopsies of the 
ascertained lesions was considered too invasive of a procedure for this study 
population to be nested within a randomized, controlled study design. HPV infection 
could not be detected directly from the biopsy specimen and the histological 
diagnosis of penile lesions could not be determined. Previous reports of flat penile 
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lesions indicate that these lesions are usually hyperplasia or low grade penile 
intraepithelial neoplasia, although a minority of lesions can be high grade (10;51). 
Potential risk factors of penile lesions, including condom use and number of 
sexual partners, were obtained through interviews as part of the main RCT. Self-
reported data may not be reliable if men exaggerated or failed to disclose 
information about important risk factors. All interviews were conducted by male 
counselors who were trained to be respectful and ensure confidentiality in order to 
help participants feel more comfortable in reporting personal information.  
Only three of the large number of HPV types were assessed for viral load in 
this study. Participants categorized as having low HPV16/18/31 viral load may have 
had a high viral load for an HPV type that was not assessed as our sample was too 
small to restrict the analysis to men with single HPV infections. Thus, viral load 
analyses should be interpreted with caution. 
 
Future Research Directions 
While only a limited number of studies have investigated the natural history of 
HPV infection among men, even fewer studies have investigated multiple risk factors 
of HPV incidence and/or persistence in men (see Chapter 2). Future studies 
investigating possible risk factors of acquisition and persistence of HPV infection 
among men are needed from more diverse study populations. Studies are especially 
needed from sub-Saharan Africa where no risk factor data are currently reported, 
except for one RCT that investigated the effect of male circumcision on the 
incidence and clearance of HPV infection in Uganda (43;44). Investigators are 
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currently evaluating the efficacy of circumcision in male to female HPV transmission 
among men enrolled in the Uganda RCT and their female sex partners (43).    
Based on previous cross-sectional analyses of baseline data from 
uncircumcised men screened for the main RCT in Kenya, laboratory-diagnosed C. 
trachomatis and N. gonorrhea infections were risk factors of HPV DNA prevalence 
(18). It remains unknown, however, whether C. trachomatis or N. gonorrhea 
infections increase the risk of incident HPV infections in men, and whether men with 
HPV and C. trachomatis or N. gonorrhea co-infections are more likely to have 
persistent HPV infections.   
Flat penile lesions were strongly associated with high-risk HPV infection and 
increased HPV16/18/31 viral load, thus circumcision may also reduce male to 
female high-risk HPV transmission. Follow-up studies are needed to determine if 
there is an effect of HPV-associated penile lesions on HPV transmission between 
sexual partners.  
Finally, future studies are needed to determine if there are associations 
between laboratory-diagnosed STIs and HPV-associated penile lesions. The 
prevalence of STIs other than HPV and HSV-2 infection were low in the VIA study 
population. Thus important associations between penile lesions and other STIs 
including C. trachomatis and N. gonorrhea might have been missed. 
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